{"gene":"LTBP2","run_date":"2026-04-28T18:30:27","timeline":{"discoveries":[{"year":1994,"finding":"LTBP-2 is a novel ~240 kDa extracellular matrix protein structurally related to LTBP-1, composed of 20 EGF-like repeats and four 8-cysteine repeats. Co-transfection experiments showed that LTBP-2 forms a high molecular weight complex with the TGF-β1 precursor, and a considerable fraction associates with extracellular matrix.","method":"cDNA cloning, recombinant protein expression in COS cells, co-transfection with TGF-β1 cDNA, immunoprecipitation, ECM association assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — original identification with multiple orthogonal methods (molecular cloning, co-transfection, IP, ECM fractionation) in a foundational, highly-cited paper","pmids":["7798248"],"is_preprint":false},{"year":1998,"finding":"The 8-Cys (TGF-bp) repeats of LTBP-2 are capable of covalently binding latent TGF-β1, demonstrated by immunoprecipitation and SDS-PAGE. Specifically, the second and third TGF-bp repeats of LTBP-2 can form covalent bonds with the latent TGF-β1 complex, analogous to LTBP-3.","method":"Immunoprecipitation, SDS-PAGE, autoradiography of radiolabeled proteins","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 — direct biochemical demonstration in a single study; note this contradicts later work showing LTBP-2 does not stably bind TGF-β in vivo","pmids":["9602168"],"is_preprint":false},{"year":1998,"finding":"Recombinant LTBP-2 assembles into fibrillar structures in fibroblast extracellular matrix. Proteolytic processing by plasmin or elastase releases an ~160-kDa fragment from matrix-bound LTBP-2, with cleavage sites localized to proline-rich regions in the N-terminal portion of LTBP-2, indicating that the matrix-binding site resides in the N-terminal ~500 amino acids.","method":"Recombinant protein expression in CHO cells, purification, biotinylation, matrix assembly assay, plasmin/elastase digestion, N-terminal amino acid sequencing of cleavage products","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted assembly, site mapping by sequencing, multiple proteases tested; single lab but multiple orthogonal methods","pmids":["9685426"],"is_preprint":false},{"year":2000,"finding":"LTBP-2 does not bind any TGF-β isoform through its 8-Cys repeats, distinguishing it from LTBP-1 and LTBP-3. A specific short TGF-β binding motif present in the 3rd 8-Cys repeat of LTBP-1 is absent in the corresponding repeat of LTBP-2; introduction of this motif into LTBP-2's 3rd 8-Cys repeat confers TGF-β·LAP binding ability, demonstrating that the motif is necessary and sufficient for TGF-β binding.","method":"In vitro binding assays with purified 8-Cys repeat fragments, domain-swap mutagenesis, molecular modeling","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis plus in vitro binding assay with rigorous domain-swap controls, highly cited","pmids":["10930463"],"is_preprint":false},{"year":2003,"finding":"LTBP-2 functions as an adhesion protein selectively for melanoma cells. The adhesive site is located in the N-terminal region of LTBP-2. Adhesion was blocked by anti-β1 integrin antibody and by antibodies against integrin subunits α3 and α6, and also by heparin, implicating β1 integrins (particularly α3β1 and α6β1) and heparan sulfate in the interaction. LTBP-2 also supported melanoma cell migration.","method":"Recombinant protein adhesion assays, recombinant fragment mapping, function-blocking integrin antibodies, heparin inhibition, immunofluorescence localization of integrins, modified Boyden chamber migration assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (fragment mapping, antibody blocking, migration assay), replicated across multiple melanoma cell lines","pmids":["12716902"],"is_preprint":false},{"year":2003,"finding":"LTBP-2 exerts antiadhesive effects on fibroblasts adhering to fibronectin. Fibroblasts plated on LTBP-2/fibronectin substrate showed markedly reduced actin stress fibers and a less adherent morphology compared to fibronectin alone. LTBP-2 did not affect adhesion to collagen type I. The antiadhesive and adhesion-mediating activities mapped to the same N-terminal proline-rich region of LTBP-2, which also bound fibronectin in vitro.","method":"Quantitative cell adhesion assays, recombinant fragment analysis, actin cytoskeleton imaging (phalloidin staining), in vitro fibronectin binding assay","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 — domain mapping with recombinant fragments plus functional cellular readout; multiple assays in a single rigorous study","pmids":["14691143"],"is_preprint":false},{"year":2007,"finding":"LTBP-2 specifically binds the amino-terminal region of fibrillin-1 but not fibrillin-2, in a Ca2+-dependent manner (Kd = 9.4 nM). The major fibrillin-1 binding site resides near the C-terminus of LTBP-2. LTBP-2 and LTBP-1 compete for the same or adjacent binding site on fibrillin-1, suggesting LTBP-2 can act as a negative modulator of latent TGF-β complex storage on microfibrils.","method":"Solid phase binding assays, overlay blotting, recombinant fragment competition assays, EDTA/Ca2+ modulation, Kd calculation, immunohistochemistry of developing human aorta","journal":"Matrix biology","confidence":"High","confidence_rationale":"Tier 1-2 — reconstituted binding with Kd determination, domain mapping, competition assay, Ca2+ dependence; multiple orthogonal methods","pmids":["17293099"],"is_preprint":false},{"year":2007,"finding":"LTBP-2 binds fibulin-5 (DANCE) and regulates elastic fiber assembly. Downregulation of LTBP-2 in human skin fibroblasts induces fibrillin-1-independent fibrillar deposition of fibulin-5 and elastin. Recombinant LTBP-2 promotes deposition of fibulin-5 onto fibrillin-1 microfibrils, indicating LTBP-2 regulates targeting of fibulin-5 to appropriate microfibrils for elastic fiber assembly.","method":"Yeast two-hybrid (implied by 'identification'), protein binding assays, siRNA knockdown of LTBP-2 in human fibroblasts, elastogenesis assay with confocal microscopy, recombinant LTBP-2 add-back experiment","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1-2 — siRNA loss-of-function plus recombinant protein rescue, multiple orthogonal readouts; highly cited","pmids":["17581631"],"is_preprint":false},{"year":2009,"finding":"LTBP-2 matrix association depends on fibrillin-1. In cultured human embryonic lung fibroblasts, LTBP-2 was not deposited into ECM until after fibronectin and fibrillin-1 networks formed. LTBP-2 failed to assemble into ECM of fibronectin-deficient mouse fibroblasts. Lentiviral shRNA silencing of fibrillin-1 profoundly disrupted LTBP-2 deposition, demonstrating fibrillin-1 is required for LTBP-2 ECM incorporation.","method":"Metabolic labeling, immunoprecipitation, temporal ECM assembly analysis, fibronectin-null fibroblasts, lentiviral shRNA knockdown of fibrillin-1, immunofluorescence co-localization","journal":"Journal of cellular physiology","confidence":"High","confidence_rationale":"Tier 2 — genetic knockdown (shRNA) plus null cell model with clear mechanistic readout; multiple orthogonal approaches","pmids":["19681046"],"is_preprint":false},{"year":2009,"finding":"Null mutations in LTBP2 cause primary congenital glaucoma. LTBP2 protein was localized to the anterior segment of the eye, specifically at the ciliary body and ciliary processes, suggesting a structural role in maintaining ciliary muscle tone and normal anterior chamber development.","method":"Homozygosity mapping, Sanger sequencing of LTBP2 in PCG families, immunohistochemistry of anterior eye segment","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 2-3 — genetic loss-of-function (null mutations) with tissue localization; mechanism inferred from anatomy rather than direct functional assay","pmids":["19361779"],"is_preprint":false},{"year":2010,"finding":"LTBP-2 has multiple heparin/heparan sulfate binding sites. Solid-phase assays identified high-affinity binding to heparin (Kd ~0.9 nM for full-length LTBP-2). Three major heparin-binding sequences reside in the N-terminal fragment, including the sequence LTEKIKKIKIV in the first large cysteine-free domain adjacent to the fibulin-5 binding site. LTBP-2 interacts with cell-surface syndecan-4 and basement membrane perlecan heparan sulfate chains.","method":"Solid-phase heparin-albumin conjugate binding assays, recombinant fragment analysis, synthetic peptide inhibition, Kd determination, EDTA/EGTA modulation, specificity controls with chondroitin sulfate","journal":"Matrix biology","confidence":"High","confidence_rationale":"Tier 1-2 — rigorous binding assays with Kd determination, domain and peptide-level mapping, specificity controls, proteoglycan interactions confirmed","pmids":["20382221"],"is_preprint":false},{"year":2012,"finding":"LTBP2 mutations cause Weill-Marchesani syndrome. The homozygous missense mutation p.Val1177Met in LTBP2 was shown to cause autosomal recessive WMS/WM-like syndrome. Electron and fluorescence microscopy of patient skin showed disruptions of the microfibrillar network in the ECM, directly linking LTBP2 dysfunction to microfibrillar network integrity.","method":"Homozygosity mapping, Sanger sequencing, light/fluorescent/electron microscopy of patient ECM","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 2-3 — genetic evidence plus direct ultrastructural demonstration of ECM disruption in patient tissue","pmids":["22539340"],"is_preprint":false},{"year":2013,"finding":"LTBP-2 competes with tropoelastin for binding to fibulin-5 and heparin, acting as a negative modulator of elastinogenesis. LTBP-2 bound fibulin-5 with Kd = 26.5 nM (similar affinity to tropoelastin-fibulin-5, Kd = 24.7 nM) and inhibited the tropoelastin-fibulin-5 interaction in a dose-dependent manner. LTBP-2 also significantly inhibited tropoelastin binding to heparin. Addition of exogenous LTBP-2 to chondrocyte cultures blocked elastinogenesis concentration-dependently.","method":"Solid-phase competitive binding assays, Kd calculation, confocal co-localization in fibroblast matrix, ear cartilage chondrocyte elastogenesis assay","journal":"Matrix biology","confidence":"High","confidence_rationale":"Tier 1-2 — quantitative competitive binding with Kd values, functional elastogenesis assay, co-localization; multiple orthogonal methods","pmids":["24148803"],"is_preprint":false},{"year":2014,"finding":"LTBP-2 is essential for formation of ciliary zonule microfibrils. Ltbp2−/− mice developed lens luxation due to compromised ciliary zonule formation. siRNA knockdown of LTBP2 in human ciliary epithelial cells disrupted microfibril meshwork formation. Supplementation with recombinant LTBP-2 rescued microfibril meshwork formation in knockdown cells and restored unfragmented bundled ciliary zonules in Ltbp2−/− mouse eyes under organ culture. Human mutant LTBP-2 proteins, despite retaining fibrillin-1-binding domains, failed to be secreted due to conformational alteration.","method":"Ltbp2 knockout mouse generation, siRNA knockdown in ciliary epithelial cells, recombinant LTBP-2 rescue in vitro and organ culture, secretion assay of mutant proteins","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1 — knockout mouse, siRNA knockdown, and recombinant protein rescue with multiple readouts; strong mechanistic evidence","pmids":["24908666"],"is_preprint":false},{"year":2015,"finding":"LTBP-2 has a single high-affinity binding site for FGF-2 (Kd = 1.1 nM) located in a central region consisting of six tandem EGF-like motifs (EGFs 9-14). This region also contains a heparin/heparan sulfate-binding site. LTBP-2 completely blocked FGF-2-stimulated fibroblast proliferation at 5-fold molar excess, demonstrating it is a potent inhibitor of FGF-2 bioactivity.","method":"Solid-phase binding assays, recombinant fragment mapping, Kd determination, FGF-2-stimulated fibroblast proliferation assay, confocal co-localization in keloid tissue","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1-2 — quantitative binding with Kd, domain mapping, functional proliferation inhibition assay; multiple orthogonal methods","pmids":["26263555"],"is_preprint":false},{"year":2015,"finding":"LTBP-2 modulates NF-κB p65 signaling in nasopharyngeal carcinoma cells. Re-expression of LTBP-2 reduced phosphorylation of p65 at Serine 536, inhibited nuclear translocation of phosphorylated p65, and impaired p65 DNA-binding ability, resulting in downregulation of p65-related gene expression and tumor suppression.","method":"Loss- and gain-of-function (siRNA/overexpression), Western blotting for p-p65(Ser536), nuclear fractionation, DNA-binding assay (EMSA implied), colony formation, angiogenesis and EMT assays","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2-3 — multiple functional readouts with defined phosphorylation endpoint; single lab","pmids":["25974126"],"is_preprint":false},{"year":2016,"finding":"A 4-bp insertion in exon 8 of LTBP2 causing a frameshift causes primary congenital glaucoma in domestic cats, with histologically confirmed arrest of aqueous humor outflow pathway development. This establishes the feline model as the first spontaneous non-rodent model of PCG linked to LTBP2 mutation and confirms LTBP2's role in anterior segment development.","method":"Candidate gene linkage analysis (LOD 18.38), Sanger sequencing, ophthalmic phenotyping, histology of anterior segment","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2-3 — genetic loss-of-function with histological mechanistic readout in an orthologous animal model","pmids":["27149523"],"is_preprint":false},{"year":2017,"finding":"A central bioactive region of LTBP-2 (an 8-Cys motif flanked by four EGF-like repeats) stimulates TGF-β1 expression and secretion in fibroblasts via phosphorylation of both Akt and p38 MAPK signaling pathways. The TGF-β1 increase was due to transcriptional upregulation (not displacement of matrix-stored TGF-β1). Anti-αVβ3 integrin antibodies partially inhibited this effect, suggesting a direct or indirect role for αVβ3 integrin as receptor.","method":"Exogenous recombinant LTBP-2 and fragment addition to fibroblasts, ELISA for TGF-β1, kinase inhibitor experiments, phosphorylation Western blots (Akt, p38), function-blocking integrin antibodies","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 — domain mapping plus signaling pathway dissection with specific inhibitors; single lab","pmids":["28991210"],"is_preprint":false},{"year":2018,"finding":"LTBP2 knockdown in trabecular meshwork cells affected TGFβ and BMP signaling pathways, ECM gene expression, and apoptosis. Effects of LTBP2 knockdown paralleled those of oxidative stress induction, suggesting LTBP2 mediates its effects on trabecular meshwork ECM and apoptosis through TGFβ and BMP signaling pathway activation.","method":"siRNA knockdown, TGFβ2 and gremlin treatment, canonical TGFβ and BMP signaling assays, ECM gene expression analysis, apoptosis assays in primary human trabecular meshwork cells","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2-3 — siRNA knockdown with multiple pathway readouts; single lab, mechanism partially defined","pmids":["29908281"],"is_preprint":false},{"year":2019,"finding":"LTBP2 knockdown in a rat dilated cardiomyopathy model reversed myocardial oxidative stress injury, fibrosis, and remodeling. The protective effects were mediated by downregulation of the NF-κB signaling pathway (reduced p65 and p52 levels). Activation of NF-κB pathway reversed the benefits of LTBP2 silencing, placing LTBP2 upstream of NF-κB in this context.","method":"siRNA knockdown in vivo (DCM rat model) and in vitro, NF-κB pathway activator co-treatment, hemodynamic measurements, collagen/ROS/cytokine quantification, Western blotting","journal":"Acta physiologica","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo and in vitro knockdown with epistasis rescue experiment placing LTBP2 upstream of NF-κB","pmids":["31512380"],"is_preprint":false},{"year":2020,"finding":"LTBP-2 is required for mechanical strength and longevity of ciliary zonular fibers but not for their initial formation. In Ltbp2−/− mice, zonular fibers appeared structurally normal at birth but began to rupture by 2 months, with fully penetrant ectopia lentis by 6 months. LTBP-2 absence reduced ultimate tensile strength by ~50% and significantly altered viscoelastic behavior. Modeling indicated mutant fibers are prone to failure during saccadic eye movement.","method":"Ltbp2 knockout mouse, 3D zonule imaging, in vivo OCT imaging, mechanical tensile testing, quasi-linear viscoelastic modeling, harmonic oscillator simulation","journal":"Matrix biology","confidence":"High","confidence_rationale":"Tier 1-2 — knockout mouse with quantitative mechanical testing and mathematical modeling; multiple orthogonal methods","pmids":["33039488"],"is_preprint":false},{"year":2020,"finding":"LTBP2 mutation in an LTBP2/TCTN3 double-heterozygous patient delayed cardiomyocyte development. Using CRISPR/Cas9-generated human pluripotent stem cells carrying the LTBP2 mutation (p.Asp736Asn), differentiation into cardiomyocytes showed delayed CM development compared to wild type, with enrichment of pathways related to cardiac development and congenital heart disease.","method":"CRISPR/Cas9 gene editing of hPSCs, hPSC differentiation into cardiomyocytes, transcriptomics at differentiation days 0/9/13, pathway enrichment analysis","journal":"Journal of cellular and molecular medicine","confidence":"Low","confidence_rationale":"Tier 3 — single mutation in a compound variant background (LTBP2+TCTN3), transcriptomics-based pathway inference; difficult to isolate LTBP2-specific effect","pmids":["33098376"],"is_preprint":false},{"year":2023,"finding":"Ltbp2−/− mice exhibit multiple organ phenotypes including altered body weight and fat mass, and effects on bone and skin development, with reduced tissue strength. Notably, tissues expressing high Ltbp2 levels, such as aorta and lung, showed no developmental or homeostatic phenotype, indicating tissue-specific roles for LTBP2 in ECM and signaling.","method":"Ltbp2 knockout mouse analysis, body composition measurement, bone and skin mechanical testing, histology","journal":"Developmental dynamics","confidence":"Medium","confidence_rationale":"Tier 2 — knockout mouse with multiple tissue phenotypes; mechanistic interpretation partially inferred","pmids":["37688792"],"is_preprint":false},{"year":2023,"finding":"HIF-1α directly binds to the LTBP2 promoter to transcriptionally activate LTBP2 expression. LTBP2 in turn interacts with LOXL1 (demonstrated by molecular docking and co-immunoprecipitation), and this interaction activates ERK signaling to promote hepatic stellate cell activation and EMT in liver fibrosis. AAV6-mediated knockdown of LTBP2 in HSCs markedly reduced CCl4-induced liver fibrosis.","method":"ChIP assay, dual-luciferase reporter assay, molecular docking, co-immunoprecipitation, AAV6-mediated in vivo knockdown, gain/loss-of-function in LX-2 cells, ERK pathway Western blotting","journal":"Cellular and molecular life sciences","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP for promoter binding, Co-IP for protein interaction, in vivo knockdown with phenotypic readout; single lab","pmids":["40244455"],"is_preprint":false},{"year":2023,"finding":"HIF-1α transcriptionally activates LTBP2 by binding its promoter. LTBP2 promotes oral mucosal fibrosis (OSF) by activating NF-κB signaling. Curcumin inhibits HIF-1α, thereby reducing LTBP2 expression and inactivating NF-κB to alleviate arecoline-induced OSF. This defines HIF-1α → LTBP2 → NF-κB as a fibrosis-promoting axis.","method":"Dual-luciferase reporter assay for HIF-1α/LTBP2 promoter interaction, siRNA knockdown, qRT-PCR, Western blotting, MTT/transwell/flow cytometry assays, ELISA","journal":"Oral diseases","confidence":"Medium","confidence_rationale":"Tier 2 — luciferase assay demonstrates direct promoter binding; functional knockdown places LTBP2 in HIF-1α/NF-κB axis; single lab","pmids":["37382472"],"is_preprint":false},{"year":2024,"finding":"CAF-secreted LTBP2 interacts with integrin α6β4 on esophageal squamous cell carcinoma cells, activating Src signaling to promote metastasis and chemoresistance. Antagonistic antibodies targeting LTBP2 increased chemotherapy susceptibility. This identifies integrin α6β4 as a functional receptor for extracellular LTBP2.","method":"Co-immunoprecipitation (LTBP2/integrin α6β4), Src phosphorylation Western blotting, antagonistic antibody treatment, invasion/metastasis assays, chemoresistance assays","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP demonstrates binding, signaling assay confirms downstream activation, antibody intervention links to functional outcome; single lab","pmids":["40245188"],"is_preprint":false},{"year":2025,"finding":"LTBP2 deficiency reduces lung fibrosis in mice. Ltbp2−/− mice exposed to bleomycin or silica showed significantly reduced fibrosis versus wild-type, with reduced TGFβ signaling and impaired fibroblast migration in vitro. Transcriptomic analysis identified LTBP2-regulated genes including the antifibrotic lncRNA Airn. LTBP2 competes with the large latent TGFβ complex (LLC) for fibrillin N-terminus binding, and its loss promotes LLC sequestration and reduces active TGFβ release. However, Ltbp2−/− mice also showed impaired airway epithelial repair.","method":"Ltbp2 knockout mouse, bleomycin and silica fibrosis models, TGFβ signaling assays (pSmad), fibroblast wound closure assay, transcriptomics, naphthalene epithelial injury model","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — knockout mouse with two independent fibrosis models, signaling assays, and in vitro functional test; preprint, not yet peer-reviewed","pmids":["40654695"],"is_preprint":true},{"year":2025,"finding":"LTBP2 knockout mice develop myxomatous mitral valve changes (histology and echocardiography). A human MVP-segregating LTBP2 mutation (V1506M knockin) reproduced the myxomatous valve phenotype. KO mice showed overexpression of TGFβ signaling targets RUNX2 and periostin in valve tissue, linking LTBP2 loss to dysregulated TGFβ signaling in valvular disease.","method":"LTBP2 knockout and knockin mouse generation, echocardiography, histology, qPCR for TGFβ target genes (periostin/POSTN, RUNX2, CTGF), exome sequencing with family segregation","journal":"European heart journal open","confidence":"Medium","confidence_rationale":"Tier 2 — both KO and KI mouse models with multiple phenotyping methods and molecular pathway readout; single lab","pmids":["39882270"],"is_preprint":false}],"current_model":"LTBP2 is a large extracellular matrix glycoprotein of the fibrillin-LTBP superfamily that, uniquely among LTBPs, does not stably bind TGF-β; instead it binds fibrillin-1 (C-terminal site, Kd ~9 nM, Ca2+-dependent), fibulin-5, FGF-2 (central EGF-like region, Kd ~1 nM), heparan sulfate proteoglycans (syndecan-4, perlecan), and integrin α6β4, thereby acting as a structural microfibril component that regulates elastic fiber assembly by competing with tropoelastin for fibulin-5 and with the large latent TGF-β complex for fibrillin-1 binding, controls TGF-β bioavailability and signaling (including Akt/p38 and NF-κB pathways), mediates selective cell adhesion and antiadhesion through its N-terminal proline-rich region, and is essential for the mechanical strength of ciliary zonular fibers and normal development of the ocular anterior segment, cardiac valves, and multiple connective tissues."},"narrative":{"teleology":[{"year":1994,"claim":"Identification of LTBP-2 as a novel ECM glycoprotein structurally related to LTBP-1 that associates with TGF-β1 precursor and the extracellular matrix established the founding member context for subsequent functional studies.","evidence":"cDNA cloning, recombinant co-transfection with TGF-β1, immunoprecipitation, and ECM association assay in COS cells","pmids":["7798248"],"confidence":"High","gaps":["Physiological significance of the TGF-β1 association was unclear","In vivo ECM localization not determined","Binding stoichiometry and affinity not measured"]},{"year":2000,"claim":"Resolving a contradiction with the 1994/1998 findings, domain-swap mutagenesis demonstrated that LTBP-2 uniquely among LTBPs lacks TGF-β binding capacity due to absence of a critical motif in its third 8-Cys repeat, fundamentally redefining its functional identity.","evidence":"In vitro binding assays with purified 8-Cys repeat fragments and domain-swap mutagenesis introducing the LTBP-1 TGF-β-binding motif into LTBP-2","pmids":["10930463"],"confidence":"High","gaps":["If not TGF-β binding, the primary biological function of LTBP-2 remained unknown","In vivo consequences of this distinction were untested"]},{"year":2003,"claim":"Mapping of dual adhesive and antiadhesive activities to the N-terminal proline-rich region of LTBP-2 revealed it as a cell-type-selective modulator of cell-matrix interactions operating through β1 integrins and heparan sulfate.","evidence":"Recombinant fragment adhesion assays, integrin-blocking antibodies, heparin inhibition on melanoma cells; antiadhesion and fibronectin-binding assays on fibroblasts","pmids":["12716902","14691143"],"confidence":"High","gaps":["Specific integrin heterodimer(s) mediating the antiadhesive effect on fibroblasts were not defined","In vivo relevance of the adhesion/antiadhesion duality was not tested"]},{"year":2007,"claim":"Two landmark findings — high-affinity Ca²⁺-dependent binding of LTBP-2 to fibrillin-1 (Kd ~9 nM) with competition against LTBP-1, and binding to fibulin-5 to regulate elastic fiber assembly — established LTBP-2 as a structural microfibril component that indirectly controls TGF-β storage and elastogenesis.","evidence":"Solid-phase binding with Kd determination and competition assays for fibrillin-1; siRNA knockdown and recombinant rescue for fibulin-5/elastin deposition in human fibroblasts","pmids":["17293099","17581631"],"confidence":"High","gaps":["Whether LTBP-2 displaces the large latent TGF-β complex from fibrillin-1 in vivo was not directly shown","Stoichiometry of LTBP-2 within microfibril bundles was unknown"]},{"year":2009,"claim":"Discovery that LTBP2 null mutations cause primary congenital glaucoma in humans, with LTBP-2 localized to the ciliary body, linked this structural ECM protein to a specific Mendelian ocular disease and anterior segment development.","evidence":"Homozygosity mapping and Sanger sequencing in PCG families; immunohistochemistry of human anterior eye segment","pmids":["19361779"],"confidence":"Medium","gaps":["Molecular mechanism by which LTBP-2 loss disrupts aqueous outflow was not determined","Whether glaucoma results from structural or signaling defects was unclear"]},{"year":2010,"claim":"Identification of multiple high-affinity heparin-binding sites and interactions with syndecan-4 and perlecan expanded the LTBP-2 interactome to heparan sulfate proteoglycans, providing a molecular basis for its cell-surface and basement membrane interactions.","evidence":"Solid-phase binding with recombinant fragments, synthetic peptide inhibition, Kd determination (~0.9 nM)","pmids":["20382221"],"confidence":"High","gaps":["Functional consequence of syndecan-4/perlecan binding on signaling or ECM assembly was not tested","Whether HSPG interactions are required for LTBP-2 ECM incorporation was not addressed"]},{"year":2013,"claim":"Quantitative competition assays showing LTBP-2 displaces tropoelastin from fibulin-5 (comparable Kd values ~25 nM) and blocks elastinogenesis in chondrocytes established LTBP-2 as a negative modulator of elastic fiber assembly.","evidence":"Competitive solid-phase binding assays with Kd determination; exogenous LTBP-2 addition to chondrocyte elastogenesis cultures","pmids":["24148803"],"confidence":"High","gaps":["In vivo elastic fiber phenotype of LTBP-2 deficiency in elastic tissues (aorta, lung) was not characterized at this point","Temporal regulation of competition was unknown"]},{"year":2014,"claim":"Ltbp2 knockout mice developed progressive lens luxation from ciliary zonule fiber failure, and recombinant LTBP-2 rescued microfibril formation in both knockdown cells and KO organ cultures, proving LTBP-2 is essential for zonular fiber integrity.","evidence":"Ltbp2−/− mice, siRNA in ciliary epithelial cells, recombinant protein rescue in vitro and organ culture, mutant protein secretion assay","pmids":["24908666"],"confidence":"High","gaps":["Whether LTBP-2 is a load-bearing structural element or an assembly catalyst was unresolved","The mechanism by which human LTBP2 mutations cause glaucoma versus ectopia lentis was unexplained"]},{"year":2015,"claim":"Discovery that LTBP-2 binds FGF-2 with very high affinity (Kd ~1 nM) through central EGF-like repeats and completely blocks FGF-2-stimulated proliferation expanded LTBP-2's role from a structural/TGF-β modulator to a broader growth factor sequestrant.","evidence":"Solid-phase binding with recombinant fragments, Kd determination, FGF-2-stimulated fibroblast proliferation inhibition assay","pmids":["26263555"],"confidence":"High","gaps":["In vivo significance of FGF-2 sequestration was not tested","Whether FGF-2 binding affects LTBP-2 matrix assembly or fibrillin interactions was unknown"]},{"year":2017,"claim":"A central bioactive fragment of LTBP-2 was shown to stimulate TGF-β1 transcription via Akt and p38 MAPK signaling, partially through αVβ3 integrin, revealing that LTBP-2 does not merely sequester growth factors but also actively triggers signaling cascades.","evidence":"Recombinant fragment addition to fibroblasts, ELISA, kinase inhibitors, phosphorylation Western blots, integrin-blocking antibodies","pmids":["28991210"],"confidence":"Medium","gaps":["The direct receptor for the LTBP-2 fragment was not definitively identified","Whether this signaling occurs during normal ECM remodeling or only pathologically was unclear","Single lab finding not independently replicated"]},{"year":2020,"claim":"Mechanical testing of Ltbp2−/− ciliary zonules quantitatively demonstrated ~50% reduction in ultimate tensile strength and altered viscoelasticity, establishing LTBP-2 as a structural reinforcer required for long-term mechanical resilience rather than initial fiber formation.","evidence":"Ltbp2 knockout mouse, tensile testing, 3D imaging, quasi-linear viscoelastic modeling, harmonic oscillator simulation of saccadic eye movement","pmids":["33039488"],"confidence":"High","gaps":["The molecular mechanism of mechanical reinforcement (cross-linking, bundling, stiffening) was not defined","Whether this mechanical role extends to other microfibril-rich tissues was unknown"]},{"year":2023,"claim":"Multiple studies converged on a HIF-1α → LTBP2 → NF-κB/ERK fibrosis-promoting axis, showing HIF-1α directly binds the LTBP2 promoter and that LTBP2 activates NF-κB signaling in fibrotic contexts and interacts with LOXL1 to activate ERK in hepatic stellate cells.","evidence":"ChIP and dual-luciferase reporter assays for HIF-1α/promoter binding; co-immunoprecipitation of LTBP2-LOXL1; AAV6-mediated in vivo knockdown reducing liver fibrosis; siRNA studies in oral fibrosis models","pmids":["40244455","37382472"],"confidence":"Medium","gaps":["Whether LTBP2-LOXL1 interaction is direct or bridged by ECM components needs confirmation beyond co-IP and docking","How extracellular LTBP2 activates intracellular NF-κB — the receptor/transducer is undefined","Replication in independent labs needed"]},{"year":2024,"claim":"Identification of integrin α6β4 as a functional cell-surface receptor for LTBP2, activating Src signaling to drive metastasis and chemoresistance in esophageal cancer, provided the first defined receptor-signaling axis for extracellular LTBP2.","evidence":"Co-immunoprecipitation of LTBP2 with integrin α6β4, Src phosphorylation assays, antagonistic antibody treatment in cancer cells","pmids":["40245188"],"confidence":"Medium","gaps":["Binding site on LTBP2 for integrin α6β4 not mapped","Whether this receptor mediates LTBP2 signaling in non-cancer contexts is unknown","Single study without reciprocal knockout validation"]},{"year":2025,"claim":"Ltbp2 knockout mice showed myxomatous mitral valve disease with TGF-β target upregulation (RUNX2, periostin), and a human knockin of a MVP-segregating LTBP2 variant recapitulated this phenotype, establishing LTBP2 as a regulator of cardiac valve homeostasis via TGF-β pathway modulation.","evidence":"KO and knockin mouse models, echocardiography, histology, qPCR for TGF-β targets, exome sequencing with family segregation","pmids":["39882270"],"confidence":"Medium","gaps":["Whether valve disease results from increased active TGF-β release or altered ECM mechanics is not resolved","Long-term progression and penetrance in heterozygotes not characterized"]},{"year":null,"claim":"Major unresolved questions include the structural basis of LTBP-2's mechanical reinforcement of microfibrils, the identity and hierarchy of cell-surface receptors mediating LTBP-2's intracellular signaling in non-cancer tissues, and why LTBP2 loss produces organ-specific phenotypes despite broad expression.","evidence":"","pmids":[],"confidence":"High","gaps":["No atomic-resolution structure of LTBP-2 or its complexes exists","The receptor hierarchy (integrin α6β4, αVβ3, HSPGs) for LTBP2 signaling is not unified","Tissue-specific phenotypic selectivity in KO mice is mechanistically unexplained"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[2,8,13,20]},{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[4,5,25]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[6,7,12,14]}],"localization":[{"term_id":"GO:0031012","term_label":"extracellular matrix","supporting_discovery_ids":[0,2,6,7,8,10,11,13]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,14,25]}],"pathway":[{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[2,6,7,8,11,12,13,20]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[15,17,19,24,25]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[9,13,16,27]}],"complexes":[],"partners":["FBN1","FBLN5","FGF2","SDC4","HSPG2","ITGB4","LOXL1"],"other_free_text":[]},"mechanistic_narrative":"LTBP2 is a large extracellular matrix glycoprotein of the fibrillin-LTBP superfamily that serves as a structural component of microfibrils and a multifunctional regulator of growth factor bioavailability, elastic fiber assembly, and connective tissue integrity. Unlike other LTBPs, LTBP2 does not stably bind TGF-β isoforms; instead it binds fibrillin-1 (Kd ~9 nM, Ca²⁺-dependent) and competes with the large latent TGF-β complex for fibrillin-1 binding, thereby modulating TGF-β storage and release, and also binds fibulin-5 (Kd ~27 nM), competing with tropoelastin to negatively regulate elastinogenesis [PMID:10930463, PMID:17293099, PMID:24148803, PMID:40654695]. LTBP2 additionally binds FGF-2 with high affinity (Kd ~1 nM) to inhibit FGF-2-driven proliferation, interacts with heparan sulfate proteoglycans (syndecan-4, perlecan) and integrin α6β4, and signals through Akt/p38, NF-κB, and Src pathways in cell-type-dependent contexts [PMID:26263555, PMID:20382221, PMID:40245188, PMID:28991210]. Loss-of-function mutations in LTBP2 cause primary congenital glaucoma and Weill-Marchesani syndrome in humans, and Ltbp2-null mice develop ectopia lentis from mechanically weakened ciliary zonular fibers, myxomatous mitral valve disease with dysregulated TGF-β signaling, and reduced fibrotic responses in the lung [PMID:19361779, PMID:22539340, PMID:33039488, PMID:39882270]."},"prefetch_data":{"uniprot":{"accession":"Q14767","full_name":"Latent-transforming growth factor beta-binding protein 2","aliases":[],"length_aa":1821,"mass_kda":195.1,"function":"May play an integral structural role in elastic-fiber architectural organization and/or assembly","subcellular_location":"Secreted, extracellular space, extracellular matrix","url":"https://www.uniprot.org/uniprotkb/Q14767/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/LTBP2","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":1208,"dependency_fraction":0.0033112582781456954},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/LTBP2","total_profiled":1310},"omim":[{"mim_id":"614819","title":"WEILL-MARCHESANI SYNDROME 3; WMS3","url":"https://www.omim.org/entry/614819"},{"mim_id":"613086","title":"GLAUCOMA 3, PRIMARY CONGENITAL, D; GLC3D","url":"https://www.omim.org/entry/613086"},{"mim_id":"602091","title":"LATENT TRANSFORMING GROWTH FACTOR-BETA-BINDING PROTEIN 2; LTBP2","url":"https://www.omim.org/entry/602091"},{"mim_id":"602090","title":"LATENT TRANSFORMING GROWTH FACTOR-BETA-BINDING PROTEIN 3; LTBP3","url":"https://www.omim.org/entry/602090"},{"mim_id":"601771","title":"CYTOCHROME P450, SUBFAMILY I, POLYPEPTIDE 1; CYP1B1","url":"https://www.omim.org/entry/601771"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"blood vessel","ntpm":337.5}],"url":"https://www.proteinatlas.org/search/LTBP2"},"hgnc":{"alias_symbol":[],"prev_symbol":["LTBP3","C14orf141"]},"alphafold":{"accession":"Q14767","domains":[{"cath_id":"2.10.25.10","chopping":"169-216","consensus_level":"high","plddt":76.4173,"start":169,"end":216},{"cath_id":"3.90.290.10","chopping":"668-735","consensus_level":"medium","plddt":77.1806,"start":668,"end":735},{"cath_id":"2.10.25.10","chopping":"857-889","consensus_level":"medium","plddt":74.7942,"start":857,"end":889},{"cath_id":"-","chopping":"975-1013_1028-1039","consensus_level":"medium","plddt":70.9663,"start":975,"end":1039},{"cath_id":"-","chopping":"1262-1305","consensus_level":"medium","plddt":70.128,"start":1262,"end":1305},{"cath_id":"3.90.290.10","chopping":"1411-1487","consensus_level":"medium","plddt":73.523,"start":1411,"end":1487},{"cath_id":"3.90.290.10","chopping":"1582-1646","consensus_level":"medium","plddt":73.2878,"start":1582,"end":1646},{"cath_id":"2.10.25.10","chopping":"1733-1776","consensus_level":"medium","plddt":70.1886,"start":1733,"end":1776}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14767","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q14767-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q14767-F1-predicted_aligned_error_v6.png","plddt_mean":58.34},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=LTBP2","jax_strain_url":"https://www.jax.org/strain/search?query=LTBP2"},"sequence":{"accession":"Q14767","fasta_url":"https://rest.uniprot.org/uniprotkb/Q14767.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q14767/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14767"}},"corpus_meta":[{"pmid":"19361779","id":"PMC_19361779","title":"Null mutations in LTBP2 cause primary congenital glaucoma.","date":"2009","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19361779","citation_count":258,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7798248","id":"PMC_7798248","title":"Identification and characterization of LTBP-2, a novel latent transforming growth factor-beta-binding protein.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7798248","citation_count":143,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19656777","id":"PMC_19656777","title":"Loss of function mutations in the gene encoding latent transforming growth factor beta binding protein 2, LTBP2, cause primary congenital glaucoma.","date":"2009","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19656777","citation_count":132,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11790802","id":"PMC_11790802","title":"Bone abnormalities in latent TGF-[beta] binding protein (Ltbp)-3-null mice indicate a role for Ltbp-3 in modulating TGF-[beta] bioavailability.","date":"2002","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/11790802","citation_count":130,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7730318","id":"PMC_7730318","title":"Isolation of a novel latent transforming growth factor-beta binding protein gene (LTBP-3).","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7730318","citation_count":123,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32826876","id":"PMC_32826876","title":"The circEPSTI1/mir-942-5p/LTBP2 axis regulates the progression of OSCC in the background of OSF via EMT and the PI3K/Akt/mTOR pathway.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32826876","citation_count":119,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17293099","id":"PMC_17293099","title":"LTBP-2 specifically interacts with the amino-terminal region of fibrillin-1 and competes with LTBP-1 for binding to this microfibrillar protein.","date":"2007","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/17293099","citation_count":113,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22539340","id":"PMC_22539340","title":"LTBP2 mutations cause Weill-Marchesani and Weill-Marchesani-like syndrome and affect disruptions in the extracellular matrix.","date":"2012","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/22539340","citation_count":107,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25187517","id":"PMC_25187517","title":"Activation of LTBP3 gene by a long noncoding RNA (lncRNA) MALAT1 transcript in mesenchymal stem cells from multiple myeloma.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25187517","citation_count":102,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20179738","id":"PMC_20179738","title":"LTBP2 null mutations in an autosomal recessive ocular syndrome with megalocornea, spherophakia, and secondary glaucoma.","date":"2010","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/20179738","citation_count":97,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28469957","id":"PMC_28469957","title":"HBx-related long non-coding RNA MALAT1 promotes cell metastasis via up-regulating LTBP3 in hepatocellular carcinoma.","date":"2017","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28469957","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22128238","id":"PMC_22128238","title":"Screening of CYP1B1 and LTBP2 genes in Saudi families with primary congenital glaucoma: genotype-phenotype correlation.","date":"2011","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/22128238","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20617341","id":"PMC_20617341","title":"A homozygous mutation in LTBP2 causes isolated microspherophakia.","date":"2010","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20617341","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23218701","id":"PMC_23218701","title":"CYP1B1, MYOC, and LTBP2 mutations in primary congenital glaucoma patients in the United States.","date":"2012","source":"American journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/23218701","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19344874","id":"PMC_19344874","title":"Oligodontia is caused by mutation in LTBP3, the gene encoding latent TGF-beta binding protein 3.","date":"2009","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19344874","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21081970","id":"PMC_21081970","title":"LTBP2 and CYP1B1 mutations and associated ocular phenotypes in the Roma/Gypsy founder population.","date":"2010","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/21081970","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12379497","id":"PMC_12379497","title":"Bone defects in latent TGF-beta binding protein (Ltbp)-3 null mice; a role for Ltbp in TGF-beta presentation.","date":"2002","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/12379497","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22025892","id":"PMC_22025892","title":"Congenital megalocornea with zonular weakness and childhood lens-related secondary glaucoma - a distinct phenotype caused by recessive LTBP2 mutations.","date":"2011","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/22025892","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12154076","id":"PMC_12154076","title":"Secretion of human latent TGF-beta-binding protein-3 (LTBP-3) is dependent on co-expression of TGF-beta.","date":"2002","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/12154076","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30006483","id":"PMC_30006483","title":"LTBP2 is secreted from lung myofibroblasts and is a potential biomarker for idiopathic pulmonary fibrosis.","date":"2018","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/30006483","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39196085","id":"PMC_39196085","title":"Identification of LTBP-2 as a plasma biomarker for right ventricular dysfunction in human pulmonary arterial hypertension.","date":"2022","source":"Nature cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/39196085","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27068007","id":"PMC_27068007","title":"Mutations in LTBP3 cause acromicric dysplasia and geleophysic dysplasia.","date":"2016","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27068007","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27911796","id":"PMC_27911796","title":"Egr2 and Egr3 in regulatory T cells cooperatively control systemic autoimmunity through Ltbp3-mediated TGF-β3 production.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/27911796","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29625025","id":"PMC_29625025","title":"LTBP3 Pathogenic Variants Predispose Individuals to Thoracic Aortic Aneurysms and Dissections.","date":"2018","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29625025","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26494287","id":"PMC_26494287","title":"Genetic analysis of the contribution of LTBP-3 to thoracic aneurysm in Marfan syndrome.","date":"2015","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/26494287","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12062452","id":"PMC_12062452","title":"Latent TGF-beta binding protein-3 (LTBP-3) requires binding to TGF-beta for secretion.","date":"2002","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/12062452","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20878956","id":"PMC_20878956","title":"The ECM protein LTBP-2 is a suppressor of esophageal squamous cell carcinoma tumor formation but higher tumor expression associates with poor patient outcome.","date":"2010","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20878956","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19681046","id":"PMC_19681046","title":"Matrix association of latent TGF-beta binding protein-2 (LTBP-2) is dependent on fibrillin-1.","date":"2009","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19681046","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27149523","id":"PMC_27149523","title":"A Mutation in LTBP2 Causes Congenital Glaucoma in Domestic Cats (Felis catus).","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27149523","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25669657","id":"PMC_25669657","title":"Mutations in the latent TGF-beta binding protein 3 (LTBP3) gene cause brachyolmia with amelogenesis imperfecta.","date":"2015","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25669657","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14691143","id":"PMC_14691143","title":"Latent TGF-beta binding protein LTBP-2 decreases fibroblast adhesion to fibronectin.","date":"2003","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/14691143","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33039488","id":"PMC_33039488","title":"Latent-transforming growth factor beta-binding protein-2 (LTBP-2) is required for longevity but not for development of zonular fibers.","date":"2020","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/33039488","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31512380","id":"PMC_31512380","title":"LTBP2 knockdown by siRNA reverses myocardial oxidative stress injury, fibrosis and remodelling during dilated cardiomyopathy.","date":"2019","source":"Acta physiologica (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/31512380","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25974126","id":"PMC_25974126","title":"NF-κB p65 Subunit Is Modulated by Latent Transforming Growth Factor-β Binding Protein 2 (LTBP2) in Nasopharyngeal Carcinoma HONE1 and HK1 Cells.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25974126","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20382221","id":"PMC_20382221","title":"LTBP-2 has multiple heparin/heparan sulfate binding sites.","date":"2010","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/20382221","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29908281","id":"PMC_29908281","title":"LTBP2 knockdown and oxidative stress affect glaucoma features including TGFβ pathways, ECM genes expression and apoptosis in trabecular meshwork cells.","date":"2018","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/29908281","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26644005","id":"PMC_26644005","title":"Co-localization of LTBP-2 with FGF-2 in fibrotic human keloid and hypertrophic scar.","date":"2015","source":"Journal of molecular histology","url":"https://pubmed.ncbi.nlm.nih.gov/26644005","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22743615","id":"PMC_22743615","title":"LTBP-2 confers pleiotropic suppression and promotes dormancy in a growth factor permissive microenvironment in nasopharyngeal carcinoma.","date":"2012","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/22743615","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18697872","id":"PMC_18697872","title":"Identification of LTBP2 on chromosome 14q as a novel candidate gene for bone mineral density variation and fracture risk association.","date":"2008","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/18697872","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27409795","id":"PMC_27409795","title":"Identification of Novel Variants in LTBP2 and PXDN Using Whole-Exome Sequencing in Developmental and Congenital Glaucoma.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27409795","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30887145","id":"PMC_30887145","title":"Genotype-phenotype correlation and expansion of orodental anomalies in LTBP3-related disorders.","date":"2019","source":"Molecular genetics and genomics : MGG","url":"https://pubmed.ncbi.nlm.nih.gov/30887145","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24148803","id":"PMC_24148803","title":"LTBP-2 competes with tropoelastin for binding to fibulin-5 and heparin, and is a negative modulator of elastinogenesis.","date":"2013","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/24148803","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29348457","id":"PMC_29348457","title":"LTBP3 promotes early metastatic events during cancer cell dissemination.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/29348457","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37163903","id":"PMC_37163903","title":"Dengzhan Shengmai capsule attenuates cardiac fibrosis in post-myocardial infarction rats by regulating LTBP2 and TGF-β1/Smad3 pathway.","date":"2023","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37163903","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27712597","id":"PMC_27712597","title":"Knockdown of Latent Transforming Growth Factor-β (TGF-β)-Binding Protein 2 (LTBP2) Inhibits Invasion and Tumorigenesis in Thyroid Carcinoma Cells.","date":"2016","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/27712597","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22515403","id":"PMC_22515403","title":"LTBP-2 acts as a novel marker in human heart failure - a preliminary study.","date":"2012","source":"Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/22515403","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7719025","id":"PMC_7719025","title":"Mapping of human and murine genes for latent TGF-beta binding protein-2 (LTBP2).","date":"1995","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/7719025","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23378721","id":"PMC_23378721","title":"Screening of the LTBP2 gene in a north Indian population with primary congenital glaucoma.","date":"2013","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/23378721","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25899461","id":"PMC_25899461","title":"New recessive truncating mutation in LTBP3 in a family with oligodontia, short stature, and mitral valve prolapse.","date":"2015","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/25899461","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12811825","id":"PMC_12811825","title":"Growth retardation as well as spleen and thymus involution in latent TGF-beta binding protein (Ltbp)-3 null mice.","date":"2003","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12811825","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22924778","id":"PMC_22924778","title":"LTBP2 gene analysis in the GLC3C-linked family and 94 CYP1B1-negative cases with primary congenital glaucoma.","date":"2012","source":"Ophthalmic genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22924778","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30380740","id":"PMC_30380740","title":"Delineation of Novel Compound Heterozygous Variants in LTBP2 Associated with Juvenile Open Angle Glaucoma.","date":"2018","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/30380740","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28991210","id":"PMC_28991210","title":"A Central Bioactive Region of LTBP-2 Stimulates the Expression of TGF-β1 in Fibroblasts via Akt and p38 Signalling Pathways.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28991210","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26263555","id":"PMC_26263555","title":"LTBP-2 Has a Single High-Affinity Binding Site for FGF-2 and Blocks FGF-2-Induced Cell Proliferation.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26263555","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22587491","id":"PMC_22587491","title":"The novel marker LTBP2 predicts all-cause and pulmonary death in patients with acute dyspnoea.","date":"2012","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/22587491","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30306291","id":"PMC_30306291","title":"Absence of LTBP-3 attenuates the aneurysmal phenotype but not spinal effects on the aorta in Marfan syndrome.","date":"2018","source":"Biomechanics and modeling in mechanobiology","url":"https://pubmed.ncbi.nlm.nih.gov/30306291","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35968244","id":"PMC_35968244","title":"LTBP2 Knockdown Promotes Ferroptosis in Gastric Cancer Cells through p62-Keap1-Nrf2 Pathway.","date":"2022","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/35968244","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30924175","id":"PMC_30924175","title":"miR-421 promotes apoptosis and suppresses metastasis of osteosarcoma cells via targeting LTBP2.","date":"2019","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30924175","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30565850","id":"PMC_30565850","title":"LTBP2-related \"Marfan-like\" phenotype in two Roma/Gypsy subjects with the LTBP2 homozygous p.R299X variant.","date":"2018","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/30565850","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22098471","id":"PMC_22098471","title":"The distribution of fibrillin-2 and LTBP-2, and their co-localisation with fibrillin-1 in adult bovine tail disc.","date":"2011","source":"Journal of anatomy","url":"https://pubmed.ncbi.nlm.nih.gov/22098471","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28727023","id":"PMC_28727023","title":"Rapid Communication: High-resolution quantitative trait loci analysis identifies LTBP2 encoding latent transforming growth factor beta binding protein 2 associated with thoracic vertebrae number in a large F2 intercross between Landrace and Korean native pigs.","date":"2017","source":"Journal of animal science","url":"https://pubmed.ncbi.nlm.nih.gov/28727023","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24867584","id":"PMC_24867584","title":"Confocal microscopy demonstrates association of LTBP-2 in fibrillin-1 microfibrils and colocalisation with perlecan in the disc cell pericellular matrix.","date":"2014","source":"Tissue & cell","url":"https://pubmed.ncbi.nlm.nih.gov/24867584","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36034756","id":"PMC_36034756","title":"LTBP2 inhibits prostate cancer progression and metastasis via the PI3K/AKT signaling pathway.","date":"2022","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36034756","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32165823","id":"PMC_32165823","title":"Novel mutations in LTBP2 identified in familial cases of primary congenital glaucoma.","date":"2020","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/32165823","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33098376","id":"PMC_33098376","title":"Novel mutations of TCTN3/LTBP2 with cellular function changes in congenital heart disease associated with polydactyly.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33098376","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26425313","id":"PMC_26425313","title":"A Possible Role for LTBP2 in the Etiology of Primary Angle Closure Glaucoma.","date":"2015","source":"Journal of ophthalmic & vision research","url":"https://pubmed.ncbi.nlm.nih.gov/26425313","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9571174","id":"PMC_9571174","title":"Alternative splicing of LTBP-3.","date":"1998","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9571174","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37688792","id":"PMC_37688792","title":"Multi-organ phenotypes in mice lacking latent TGFβ binding protein 2 (LTBP2).","date":"2023","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/37688792","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35352826","id":"PMC_35352826","title":"Expanding genotypic and phenotypic spectrums of LTBP3 variants in dental anomalies and short stature syndrome.","date":"2022","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35352826","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27293371","id":"PMC_27293371","title":"Screening of the LTBP2 gene in 214 Chinese sporadic CYP1B1-negative patients with primary congenital glaucoma.","date":"2016","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/27293371","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16223572","id":"PMC_16223572","title":"Induction of human LTBP-3 promoter activity by TGF-beta1 is mediated by Smad3/4 and AP-1 binding elements.","date":"2005","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/16223572","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28384041","id":"PMC_28384041","title":"Candidate Gene Analysis Identifies Mutations in CYP1B1 and LTBP2 in Indian Families with Primary Congenital Glaucoma.","date":"2017","source":"Genetic testing and molecular biomarkers","url":"https://pubmed.ncbi.nlm.nih.gov/28384041","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29751740","id":"PMC_29751740","title":"Next-generation sequencing reveals a new mutation in the LTBP2 gene associated with microspherophakia in a Spanish family.","date":"2018","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29751740","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9602168","id":"PMC_9602168","title":"8-Cysteine TGF-BP structural motifs are the site of covalent binding between mouse LTBP-3, LTBP-2, and latent TGF-beta 1.","date":"1998","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/9602168","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36482906","id":"PMC_36482906","title":"Identification of LTBP2 gene polymorphisms and their association with thoracolumbar vertebrae number, body size, and carcass traits in Dezhou donkeys.","date":"2022","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36482906","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38454800","id":"PMC_38454800","title":"SGLT2i improves kidney senescence by down-regulating the expression of LTBP2 in SAMP8 mice.","date":"2024","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38454800","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32452514","id":"PMC_32452514","title":"Common variants in LTBP3 gene contributed to the risk of hip osteoarthritis in Han Chinese population.","date":"2020","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/32452514","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39634285","id":"PMC_39634285","title":"Sodium Propionate Alleviates Atopic Dermatitis by Inhibiting Ferroptosis via Activation of LTBP2/FABP4 Signaling Pathway.","date":"2024","source":"Journal of inflammation research","url":"https://pubmed.ncbi.nlm.nih.gov/39634285","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33958902","id":"PMC_33958902","title":"A Pedigree Report of a Rare Case of Weill-Marchesani Syndrome with New Compound Heterozygous LTBP2 Mutations.","date":"2021","source":"Risk management and healthcare policy","url":"https://pubmed.ncbi.nlm.nih.gov/33958902","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25858550","id":"PMC_25858550","title":"Latent transforming growth factor-β binding proteins (LTBP-1 and LTBP-2) and gingiva keratinization.","date":"2015","source":"Oral diseases","url":"https://pubmed.ncbi.nlm.nih.gov/25858550","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40633755","id":"PMC_40633755","title":"Lactate Promotes Collagen Expression, Proliferation, and Migration through H3K18 Lactylation-Dependent Stimulation of LTBP3/TGF-β1 Axis in Keloid Fibroblasts.","date":"2025","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/40633755","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34535142","id":"PMC_34535142","title":"Compound heterozygous mutations in the LTBP2 gene associated with microspherophakia in a Chinese patient: a case report and literature review.","date":"2021","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/34535142","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37382472","id":"PMC_37382472","title":"Curcumin relieves arecoline-induced oral submucous fibrosis via inhibiting the LTBP2/NF-κB axis.","date":"2023","source":"Oral diseases","url":"https://pubmed.ncbi.nlm.nih.gov/37382472","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32432408","id":"PMC_32432408","title":"Bi-allelic loss-of-function novel variants in LTBP3-related skeletal dysplasia: Report of first patient from India.","date":"2020","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/32432408","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40245188","id":"PMC_40245188","title":"Targeting LTBP2 Derived from Cancer-Associated Fibroblasts Sensitizes Esophageal Squamous Cell Carcinoma to Chemotherapy.","date":"2025","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/40245188","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35235125","id":"PMC_35235125","title":"CircWHSC1 expedites cervical cancer progression via miR-532-3p/LTBP2 axis.","date":"2022","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35235125","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37864077","id":"PMC_37864077","title":"Plasma LTBP2 as a potential biomarker in differential diagnosis of connective tissue disease-associated interstitial lung disease and idiopathic pulmonary fibrosis: a pilot study.","date":"2023","source":"Clinical and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37864077","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34573388","id":"PMC_34573388","title":"A Rare Case of Brachyolmia with Amelogenesis Imperfecta Caused by a New Pathogenic Splicing Variant in LTBP3.","date":"2021","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/34573388","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27537365","id":"PMC_27537365","title":"Correction: A Mutation in LTBP2 Causes Congenital Glaucoma in Domestic Cats (Felis catus).","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27537365","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32207437","id":"PMC_32207437","title":"Genetic mapping of autosomal recessive microspherophakia to chromosome 14q24.3 in a consanguineous Pakistani family and screening of exon 36 of LTBP2 gene.","date":"2020","source":"JPMA. The Journal of the Pakistan Medical Association","url":"https://pubmed.ncbi.nlm.nih.gov/32207437","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40244455","id":"PMC_40244455","title":"HIF-1α/LTBP2 axis activate HSCs to promote liver fibrosis by interacting with LOXL1 via the ERK pathway.","date":"2025","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/40244455","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34906192","id":"PMC_34906192","title":"Novel LTBP3 mutations associated with thoracic aortic aneurysms and dissections.","date":"2021","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/34906192","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29397611","id":"PMC_29397611","title":"[The expression of LTBP2 in breast cancer and its clinical significance].","date":"2018","source":"Zhonghua yi xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/29397611","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39882270","id":"PMC_39882270","title":"Characterization of LTBP2 mutation causing mitral valve prolapse.","date":"2025","source":"European heart journal open","url":"https://pubmed.ncbi.nlm.nih.gov/39882270","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38222456","id":"PMC_38222456","title":"Identification and phenotypic analysis of novel LTBP2 mutations in a Chinese cohort with congenital ectopia lentis.","date":"2023","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/38222456","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38577985","id":"PMC_38577985","title":"LTBP2 regulates cisplatin resistance in GC cells via activation of the NF-κB2/BCL3 pathway.","date":"2024","source":"Genetics and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/38577985","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39432401","id":"PMC_39432401","title":"Trabecular Meshwork Abnormalities in a Model of Congenital Glaucoma Due to LTBP2 Mutation.","date":"2024","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/39432401","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34946872","id":"PMC_34946872","title":"LTBP3 Frameshift Variant in British Shorthair Cats with Complex Skeletal Dysplasia.","date":"2021","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/34946872","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33766794","id":"PMC_33766794","title":"Alveolar capillary dysplasia without misalignment of pulmonary veins, hyperinflammation, megalocornea and overgrowth - Association with a homozygous 2bp-insertion in LTBP2?","date":"2021","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33766794","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40654695","id":"PMC_40654695","title":"Latent transforming growth factor binding protein-2 (LTBP2), an IPF biomarker of clinical decline, promotes TGF-beta signaling and lung fibrosis in mice.","date":"2025","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/40654695","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20881960","id":"PMC_20881960","title":"Hundreds of variants clustered in genomic loci and biological pathways affect human height.","date":"2010","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/20881960","citation_count":1451,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9150447","id":"PMC_9150447","title":"Latent transforming growth factor-beta: structural features and mechanisms of activation.","date":"1997","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/9150447","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27252363","id":"PMC_27252363","title":"Regulation of the Bioavailability of TGF-β and TGF-β-Related Proteins.","date":"2016","source":"Cold Spring Harbor perspectives in biology","url":"https://pubmed.ncbi.nlm.nih.gov/27252363","citation_count":329,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10743502","id":"PMC_10743502","title":"Latent transforming growth factor-beta binding proteins (LTBPs)--structural extracellular matrix proteins for targeting TGF-beta action.","date":"1999","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/10743502","citation_count":241,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10930463","id":"PMC_10930463","title":"Specific sequence motif of 8-Cys repeats of TGF-beta binding proteins, LTBPs, creates a hydrophobic interaction surface for binding of small latent TGF-beta.","date":"2000","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/10930463","citation_count":234,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20551380","id":"PMC_20551380","title":"Proteomics characterization of extracellular space components in the human aorta.","date":"2010","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/20551380","citation_count":231,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16893474","id":"PMC_16893474","title":"Elastic fibres in health and disease.","date":"2006","source":"Expert reviews in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16893474","citation_count":183,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9709808","id":"PMC_9709808","title":"Extracellular matrix-associated transforming growth factor-beta: role in cancer cell growth and invasion.","date":"1998","source":"Advances in cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9709808","citation_count":175,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11104663","id":"PMC_11104663","title":"The latent transforming growth factor beta binding protein (LTBP) family.","date":"2000","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/11104663","citation_count":139,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23533145","id":"PMC_23533145","title":"In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine.","date":"2013","source":"Proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/23533145","citation_count":138,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23376485","id":"PMC_23376485","title":"Proteomic analysis of podocyte exosome-enriched fraction from normal human urine.","date":"2013","source":"Journal of proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/23376485","citation_count":126,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28327460","id":"PMC_28327460","title":"Comprehensive proteomic characterization of stem cell-derived extracellular matrices.","date":"2017","source":"Biomaterials","url":"https://pubmed.ncbi.nlm.nih.gov/28327460","citation_count":125,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17581631","id":"PMC_17581631","title":"Latent TGF-beta-binding protein 2 binds to DANCE/fibulin-5 and regulates elastic fiber assembly.","date":"2007","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/17581631","citation_count":101,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21362503","id":"PMC_21362503","title":"Protein profile of exosomes from trabecular meshwork cells.","date":"2011","source":"Journal of proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/21362503","citation_count":86,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12508121","id":"PMC_12508121","title":"The DNA sequence and analysis of human chromosome 14.","date":"2003","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/12508121","citation_count":80,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24908666","id":"PMC_24908666","title":"Latent TGF-β binding protein-2 is essential for the development of ciliary zonule microfibrils.","date":"2014","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24908666","citation_count":80,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25429064","id":"PMC_25429064","title":"Meta-analysis of genome-wide association studies of adult height in East Asians identifies 17 novel loci.","date":"2014","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25429064","citation_count":77,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17474147","id":"PMC_17474147","title":"Systematic identification of SH3 domain-mediated human protein-protein interactions by peptide array target screening.","date":"2007","source":"Proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/17474147","citation_count":66,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9685426","id":"PMC_9685426","title":"Recombinant latent transforming growth factor beta-binding protein 2 assembles to fibroblast extracellular matrix and is susceptible to proteolytic processing and release.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9685426","citation_count":63,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27559042","id":"PMC_27559042","title":"Glycoproteomics Reveals Decorin Peptides With Anti-Myostatin Activity in Human Atrial Fibrillation.","date":"2016","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/27559042","citation_count":54,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19182256","id":"PMC_19182256","title":"Exploring functional candidate genes for genetic association in german patients with pseudoexfoliation syndrome and pseudoexfoliation glaucoma.","date":"2009","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/19182256","citation_count":52,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19453261","id":"PMC_19453261","title":"High-density association study of 383 candidate genes for volumetric BMD at the femoral neck and lumbar spine among older men.","date":"2009","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/19453261","citation_count":52,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21041550","id":"PMC_21041550","title":"The identification of a novel locus for mandibular prognathism in the Han Chinese population.","date":"2010","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/21041550","citation_count":51,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24803312","id":"PMC_24803312","title":"Osteopontin and latent-TGF β binding-protein 2 as potential diagnostic markers for HBV-related hepatocellular carcinoma.","date":"2014","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24803312","citation_count":50,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27068509","id":"PMC_27068509","title":"Extracellular matrix remodelling in response to venous hypertension: proteomics of human varicose veins.","date":"2016","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/27068509","citation_count":49,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12716902","id":"PMC_12716902","title":"Latent transforming growth factor-beta-binding protein 2 is an adhesion protein for melanoma cells.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12716902","citation_count":48,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15063762","id":"PMC_15063762","title":"Genetic variations in humans associated with differences in the course of hepatitis C.","date":"2004","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15063762","citation_count":47,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52729,"output_tokens":6237,"usd":0.125871},"stage2":{"model":"claude-opus-4-6","input_tokens":9938,"output_tokens":4034,"usd":0.22581},"total_usd":0.760836,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":67010,"output_tokens":8181,"usd":0.161873},"round2_rules_fired":"R2","round2_stage2":{"model":"claude-opus-4-6","input_tokens":12191,"output_tokens":4156,"usd":0.247282}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"LTBP-2 was identified as a novel extracellular matrix protein structurally related to LTBP-1 and fibrillins, synthesized as a 240-kDa protein by human fibroblasts. Co-transfection of LTBP-2 and TGF-β1 cDNAs showed that LTBP-2 forms a high molecular weight complex with the TGF-β1 precursor, and a considerable fraction associates with the extracellular matrix.\",\n      \"method\": \"Co-transfection assay, cDNA library cloning, metabolic labeling, SDS-PAGE\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original identification with reconstitution-style co-transfection and biochemical characterization\",\n      \"pmids\": [\"7798248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The second and third 8-cysteine TGF-binding protein (TGF-bp) repeats of mouse LTBP-3 covalently bind latent TGF-β1, and the homologous TGF-bp repeats of mouse LTBP-2 show a similar capability for covalent binding to the small latent TGF-β1 complex via disulfide bonds.\",\n      \"method\": \"Immunoprecipitation, SDS-PAGE, autoradiography\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct biochemical assay demonstrating covalent interaction; single study\",\n      \"pmids\": [\"9602168\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"LTBP-2 has antiadhesive activity: fibroblasts do not adhere to full-length LTBP-2, and LTBP-2 disrupts fibroblast adhesion morphology and actin stress fibers on fibronectin substrates. The antiadhesive and weak adhesion-mediating activities map to the NH2-terminal proline-rich region of LTBP-2, which also binds fibronectin in vitro.\",\n      \"method\": \"Quantitative cell adhesion assay, recombinant fragment analysis, actin staining, in vitro binding assay\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with domain mapping and multiple functional readouts in a single study\",\n      \"pmids\": [\"14691143\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"LTBP-2 specifically binds the amino-terminal region of fibrillin-1 (but not fibrillin-2) in a Ca2+-dependent manner (Kd ≈ 9.4 nM), with the major fibrillin-1 binding site located near the carboxyl-terminus of LTBP-2. LTBP-2 and LTBP-1 share the same or closely proximal binding site on fibrillin-1, allowing competitive displacement, suggesting LTBP-2 may negatively modulate large latent TGF-β complex storage on microfibrils.\",\n      \"method\": \"Solid phase binding assay, overlay blotting, competitive binding assay with recombinant fragments, EDTA/Ca2+ chelation, immunohistochemistry\",\n      \"journal\": \"Matrix biology : journal of the International Society for Matrix Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with Kd determination, domain mapping, competitive binding, and tissue localization\",\n      \"pmids\": [\"17293099\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Matrix association of LTBP-2 in cultured human embryonic lung fibroblasts depends on a pre-formed fibrillin-1 network. LTBP-2 failed to assemble to ECM of fibronectin-deficient mouse fibroblasts and co-localized transiently with fibronectin. Lentiviral shRNA silencing of fibrillin-1 profoundly disrupted LTBP-2 ECM deposition.\",\n      \"method\": \"Metabolic labeling, immunoprecipitation, shRNA knockdown, immunofluorescence co-localization, fibronectin-null fibroblasts\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockdown combined with null-cell system and biochemical fractionation, multiple orthogonal approaches\",\n      \"pmids\": [\"19681046\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Null mutations in LTBP2 cause primary congenital glaucoma (PCG). LTBP2 protein was confirmed to localize in the anterior segment of the eye, at the ciliary body and ciliary process, suggesting a structural role in maintaining ciliary muscle tone and normal anterior chamber development.\",\n      \"method\": \"Homozygosity mapping, Sanger sequencing, immunohistochemistry of anterior segment\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple independent consanguineous families, loss-of-function mutations with defined anatomical localization\",\n      \"pmids\": [\"19361779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"LTBP-2 has multiple heparin/heparan sulfate binding sites. Full-length LTBP-2 binds heparin-albumin conjugate with Kd ≈ 0.9 nM. The N-terminal fragment contains the highest-affinity heparin-binding sites (Kd ≈ 0.7 nM), including sequence LTEKIKKIKIV in the first large cysteine-free domain. LTBP-2 interacts with cell-surface syndecan-4 (but not syndecan-2) and with perlecan heparan sulfate chains in a heparin-inhibitable manner.\",\n      \"method\": \"Solid phase binding assay, competitive inhibition with synthetic peptides, EDTA/EGTA chelation, recombinant fragment analysis\",\n      \"journal\": \"Matrix biology : journal of the International Society for Matrix Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with Kd measurements, domain mapping, peptide inhibition, and specificity controls\",\n      \"pmids\": [\"20382221\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Homozygous missense mutation (p.Val1177Met) in LTBP2 causes Weill-Marchesani syndrome with disruption of the microfibrillar network in the ECM of patient skin, as visualized by light, fluorescent, and electron microscopy, directly linking LTBP2 to fibrillin-containing microfibril integrity.\",\n      \"method\": \"Homozygosity mapping, Sanger sequencing, light/fluorescence/electron microscopy of patient skin ECM\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — patient-derived tissue ultrastructural analysis with genotype correlation; single study\",\n      \"pmids\": [\"22539340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"LTBP-2 binds fibulin-5 with Kd ≈ 26 nM (similar affinity to tropoelastin-fibulin-5, Kd ≈ 25 nM) and competitively inhibits the tropoelastin–fibulin-5 interaction in a dose-dependent manner. LTBP-2 also inhibits heparin binding to tropoelastin. Exogenous LTBP-2 blocks elastinogenesis in chondrocyte cultures concentration-dependently, establishing LTBP-2 as a negative modulator of elastic fiber assembly.\",\n      \"method\": \"Solid phase binding assay, competitive binding assay, confocal microscopy, ear cartilage chondrocyte culture elastinogenesis assay\",\n      \"journal\": \"Matrix biology : journal of the International Society for Matrix Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with Kd determination, competitive binding, and functional elastinogenesis assay\",\n      \"pmids\": [\"24148803\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LTBP-2 has a single high-affinity binding site for FGF-2 (Kd ≈ 1.1 nM) located in a central region consisting of six tandem EGF-like motifs (EGFs 9–14). A 5-fold molar excess of LTBP-2 completely negates FGF-2-stimulated fibroblast proliferation, identifying LTBP-2 as a potent extracellular inhibitor of FGF-2 bioactivity.\",\n      \"method\": \"Solid phase binding assay with recombinant fragments, Kd determination, cell proliferation assay, confocal microscopy\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with Kd measurement, domain mapping, and functional proliferation inhibition assay\",\n      \"pmids\": [\"26263555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"A central bioactive region of LTBP-2 (an 8-Cys motif flanked by four EGF-like repeats) stimulates TGF-β1 expression and secretion in fibroblasts via phosphorylation of Akt and p38 MAPK signaling pathways. This TGF-β1 upregulation is partially inhibited by anti-αVβ3 integrin antibodies, suggesting indirect involvement of this integrin as a potential receptor.\",\n      \"method\": \"Recombinant LTBP-2 fragment addition to fibroblast cultures, ELISA for TGF-β1, kinase inhibitor experiments, anti-integrin blocking antibodies, phosphorylation analysis\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — domain mapping with functional signaling assay; receptor identity remains inconclusive\",\n      \"pmids\": [\"28991210\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LTBP-2 and FGF-2 strongly co-localize in the ECM of fibrotic keloid and hypertrophic scar tissue, identified as elastic fibres by fibrillin-1 and elastin immunostaining, suggesting that elevated LTBP-2 sequesters FGF-2 on elastic fibres in fibrotic tissues.\",\n      \"method\": \"Confocal microscopy, immunofluorescence co-localization, qPCR\",\n      \"journal\": \"Journal of molecular histology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — co-localization in tissue; functional interaction inferred from prior in vitro data\",\n      \"pmids\": [\"26644005\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In LTBP-2 knockout mice, zonular fibers appear morphologically normal at birth but begin to rupture by 2 months and produce fully penetrant ectopia lentis by 6 months. LTBP-2 deficiency reduces ultimate tensile strength of the zonule by ~50% and alters viscoelastic behavior, without affecting fiber number, diameter, or coaxial organization, establishing LTBP-2 as essential for mechanical strength and longevity but not formation of zonular fibers.\",\n      \"method\": \"LTBP-2 knockout mouse model, 3D imaging, in vivo optical coherence tomography, stress/strain mechanical testing, quasi-linear viscoelastic modelling\",\n      \"journal\": \"Matrix biology : journal of the International Society for Matrix Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse with quantitative biomechanical readout and multiple in vivo phenotyping methods; strong mechanistic conclusion\",\n      \"pmids\": [\"33039488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Re-expression of LTBP-2 in NPC cells reduces phosphorylation of NF-κB p65 at Serine 536, inhibits nuclear localization of active phosphorylated p65, and impairs p65 DNA-binding ability, resulting in downregulation of p65-related gene expression, establishing LTBP-2 as a modulator of the canonical NF-κB signaling pathway.\",\n      \"method\": \"Loss- and gain-of-function transfection, phosphorylation analysis by Western blot, nuclear fractionation, EMSA/DNA-binding assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal functional assays; single lab study\",\n      \"pmids\": [\"25974126\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A 4-bp insertion in exon 8 of feline LTBP2 generates a frameshift eliminating functional domains and causes primary congenital glaucoma in domestic cats, with histologically confirmed arrest in postnatal development of aqueous humor outflow pathways in the anterior segment. This provides the first spontaneous non-rodent model confirming LTBP2's essential structural role in anterior chamber development.\",\n      \"method\": \"STR linkage analysis (LOD 18.38), Sanger sequencing, histological examination of anterior segment, breeding colony phenotyping\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — fully penetrant KO-equivalent model with histological mechanism, replicated across multiple animals\",\n      \"pmids\": [\"27149523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"LTBP2 knockdown in trabecular meshwork cells affects canonical TGF-β and BMP signaling pathways, expression of ECM-related genes, and apoptosis, with effects paralleling those of oxidative stress induction, suggesting LTBP2 mediates ECM and apoptotic regulation through TGF-β and BMP pathway activation.\",\n      \"method\": \"siRNA knockdown, TGF-β2/gremlin exposure, pathway reporter assays in primary human trabecular meshwork cells\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KD with defined pathway readout; single lab, multiple pathway endpoints\",\n      \"pmids\": [\"29908281\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"LTBP2 knockout mice show multi-organ phenotypes including altered body weight, fat mass, and defects in bone and skin development affecting tissue strength. Aorta and lung, despite high Ltbp2 expression, do not show developmental or homeostatic phenotype, indicating tissue-specific roles. LTBP2 acts through direct ECM effects and signaling pathways regulating the ECM.\",\n      \"method\": \"Ltbp2-/- mouse model, body composition analysis, bone and skin biomechanical testing, histology\",\n      \"journal\": \"Developmental dynamics : an official publication of the American Association of Anatomists\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse with multiple organ phenotyping; mechanistic pathways not fully resolved\",\n      \"pmids\": [\"37688792\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"LTBP-2 secreted by cancer-associated fibroblasts (CAFs) binds integrin α6β4 on esophageal squamous cell carcinoma cells (identified as a functional receptor by Co-IP and functional blocking), activating Src signaling to drive metastasis and chemoresistance. Targeting LTBP2 with antagonistic antibodies markedly increases ESCC cell susceptibility to chemotherapy.\",\n      \"method\": \"Co-immunoprecipitation, integrin blocking antibodies, Src signaling assays, antagonistic antibody functional assays, in vitro and in vivo tumor models\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor identification by Co-IP with functional blocking validation; single study\",\n      \"pmids\": [\"40245188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"LTBP2 promotes TGF-β signaling and lung fibrosis: Ltbp2-/- mice exposed to bleomycin or silica have significantly reduced fibrosis with reduced TGF-β signaling. The proposed mechanism is that LTBP-2 competes with the large latent TGF-β complex (LLC) for binding to the N-terminus of fibrillin, promoting LLC release and active TGF-β bioavailability. Isolated Ltbp2-/- fibroblasts show impaired migration in wound-closure assay.\",\n      \"method\": \"Ltbp2-/- mouse model, bleomycin/silica fibrosis models, TGF-β signaling assays, in vitro wound closure assay, transcriptomic analysis\",\n      \"journal\": \"bioRxiv : the preprint server for biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse with two independent fibrosis models and in vitro functional assay; preprint, not yet peer-reviewed\",\n      \"pmids\": [\"40654695\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"LTBP2 knockout mice develop myxomatous mitral valve changes (7/9 KO vs 0/7 controls by histology and echocardiography), and a human LTBP2 V1506M knockin mouse recapitulates the valve phenotype. KO mice overexpress TGF-β signaling targets RUNX2 and periostin in valve tissue, establishing LTBP2 as a regulator of valve integrity through TGF-β pathway modulation.\",\n      \"method\": \"KO and knockin mouse models, echocardiography, histology, qPCR for TGF-β signaling targets, exome sequencing and segregation analysis in human family\",\n      \"journal\": \"European heart journal open\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — two mouse genetic models with quantitative phenotyping and pathway analysis; single study\",\n      \"pmids\": [\"39882270\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In feline LTBP2-mutation PCG model, elastic fibers in trabecular meshwork (TM) are discontinuous and disorganized by 2 weeks postnatally, followed by reduced intertrabecular space by 5 weeks, and morphological TM cell elongation and attenuation by 12 weeks, directly linking LTBP2 to ECM structural integrity of the TM outflow pathway.\",\n      \"method\": \"Transmission electron microscopy, quantitative morphological assessment, postnatal time-series analysis in homozygous LTBP2-mutant cats vs. controls\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ultrastructural characterization in a genetic animal model at defined developmental time points\",\n      \"pmids\": [\"39432401\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"LTBP2 is secreted from lung myofibroblasts and its expression is upregulated at mRNA and protein levels by TGF-β1 in human lung myofibroblasts, indicating a TGF-β1–driven regulatory circuit in pulmonary fibrosis.\",\n      \"method\": \"FACS sorting of lung fibroblast populations, microarray analysis, TGF-β1 stimulation of human myofibroblasts, ELISA of serum LTBP2\",\n      \"journal\": \"Clinical science (London, England : 1979)\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — TGF-β1 induction shown in vitro but mechanistic pathway not resolved; mainly correlative\",\n      \"pmids\": [\"30006483\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"HIF-1α promotes LTBP2 expression by directly binding to the LTBP2 promoter region (established by ChIP and dual-luciferase assay), and LTBP2 interacts with LOXL1 (established by molecular docking and Co-IP) via the ERK signaling pathway to promote hepatic stellate cell activation and epithelial-mesenchymal transition in liver fibrosis. AAV6-mediated knockdown of LTBP2 in HSCs alleviates CCl4-induced liver fibrosis.\",\n      \"method\": \"ChIP assay, dual-luciferase reporter, Co-IP, molecular docking, AAV6 knockdown in mice, gain/loss-of-function in LX-2 cells, CCl4 mouse model\",\n      \"journal\": \"Cellular and molecular life sciences : CMLS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods identifying upstream regulator and downstream binding partner with in vivo validation; single study\",\n      \"pmids\": [\"40244455\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LTBP2 mutation in human pluripotent stem cells delays cardiomyocyte development compared to wild type, as demonstrated by transcriptomic analysis enriched in cardiac development and congenital heart disease pathways during differentiation.\",\n      \"method\": \"CRISPR/Cas9-generated hPSC mutations, cardiomyocyte differentiation, transcriptomic analysis on days 0, 9, and 13\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single study, transcriptomic readout without direct mechanistic validation of LTBP2 function in cardiac development\",\n      \"pmids\": [\"33098376\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"LTBP2 is a large extracellular matrix glycoprotein that localizes to fibrillin-1-containing microfibrils in a fibrillin-1-dependent manner; it binds the N-terminal region of fibrillin-1 (Kd ~9 nM) and competes with LTBP-1 and the large latent TGF-β complex for this site, thereby modulating TGF-β bioavailability and signaling (including via Akt/p38 and ERK pathways), while also binding and sequestering FGF-2 (Kd ~1 nM) through a central EGF-like domain, interacting with heparan sulfate proteoglycans (syndecan-4, perlecan), competitively inhibiting tropoelastin–fibulin-5 interactions to negatively regulate elastogenesis, exerting antiadhesive effects on fibroblasts via its N-terminal domain, and providing essential mechanical strength to zonular fibers and trabecular meshwork ECM; loss-of-function mutations cause primary congenital glaucoma, microspherophakia, Weill-Marchesani syndrome, and myxomatous mitral valve disease, while CAF-secreted LTBP2 can also activate Src signaling through integrin α6β4 to drive tumor progression.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper and extract discoveries only from KEEP papers.\n\n**Classification notes:**\n- Papers about LTBP3, LTBP1, LTBP4 → EXCLUDE (different family members)\n- Paper [6] circEPSTI1/LTBP2 → involves LTBP2 as target but mechanism is about circRNA; the LTBP2 mechanistic findings are included\n- Papers about LTBP2 in various organisms (cat, mouse knockout) → KEEP as orthologs\n- Gene mapping/cDNA papers without mechanistic findings → noted\n- Pure biomarker/expression papers → EXCLUDE from discoveries\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"LTBP-2 is a novel ~240 kDa extracellular matrix protein structurally related to LTBP-1, composed of 20 EGF-like repeats and four 8-cysteine repeats. Co-transfection experiments showed that LTBP-2 forms a high molecular weight complex with the TGF-β1 precursor, and a considerable fraction associates with extracellular matrix.\",\n      \"method\": \"cDNA cloning, recombinant protein expression in COS cells, co-transfection with TGF-β1 cDNA, immunoprecipitation, ECM association assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — original identification with multiple orthogonal methods (molecular cloning, co-transfection, IP, ECM fractionation) in a foundational, highly-cited paper\",\n      \"pmids\": [\"7798248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The 8-Cys (TGF-bp) repeats of LTBP-2 are capable of covalently binding latent TGF-β1, demonstrated by immunoprecipitation and SDS-PAGE. Specifically, the second and third TGF-bp repeats of LTBP-2 can form covalent bonds with the latent TGF-β1 complex, analogous to LTBP-3.\",\n      \"method\": \"Immunoprecipitation, SDS-PAGE, autoradiography of radiolabeled proteins\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct biochemical demonstration in a single study; note this contradicts later work showing LTBP-2 does not stably bind TGF-β in vivo\",\n      \"pmids\": [\"9602168\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Recombinant LTBP-2 assembles into fibrillar structures in fibroblast extracellular matrix. Proteolytic processing by plasmin or elastase releases an ~160-kDa fragment from matrix-bound LTBP-2, with cleavage sites localized to proline-rich regions in the N-terminal portion of LTBP-2, indicating that the matrix-binding site resides in the N-terminal ~500 amino acids.\",\n      \"method\": \"Recombinant protein expression in CHO cells, purification, biotinylation, matrix assembly assay, plasmin/elastase digestion, N-terminal amino acid sequencing of cleavage products\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted assembly, site mapping by sequencing, multiple proteases tested; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"9685426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"LTBP-2 does not bind any TGF-β isoform through its 8-Cys repeats, distinguishing it from LTBP-1 and LTBP-3. A specific short TGF-β binding motif present in the 3rd 8-Cys repeat of LTBP-1 is absent in the corresponding repeat of LTBP-2; introduction of this motif into LTBP-2's 3rd 8-Cys repeat confers TGF-β·LAP binding ability, demonstrating that the motif is necessary and sufficient for TGF-β binding.\",\n      \"method\": \"In vitro binding assays with purified 8-Cys repeat fragments, domain-swap mutagenesis, molecular modeling\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis plus in vitro binding assay with rigorous domain-swap controls, highly cited\",\n      \"pmids\": [\"10930463\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"LTBP-2 functions as an adhesion protein selectively for melanoma cells. The adhesive site is located in the N-terminal region of LTBP-2. Adhesion was blocked by anti-β1 integrin antibody and by antibodies against integrin subunits α3 and α6, and also by heparin, implicating β1 integrins (particularly α3β1 and α6β1) and heparan sulfate in the interaction. LTBP-2 also supported melanoma cell migration.\",\n      \"method\": \"Recombinant protein adhesion assays, recombinant fragment mapping, function-blocking integrin antibodies, heparin inhibition, immunofluorescence localization of integrins, modified Boyden chamber migration assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (fragment mapping, antibody blocking, migration assay), replicated across multiple melanoma cell lines\",\n      \"pmids\": [\"12716902\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"LTBP-2 exerts antiadhesive effects on fibroblasts adhering to fibronectin. Fibroblasts plated on LTBP-2/fibronectin substrate showed markedly reduced actin stress fibers and a less adherent morphology compared to fibronectin alone. LTBP-2 did not affect adhesion to collagen type I. The antiadhesive and adhesion-mediating activities mapped to the same N-terminal proline-rich region of LTBP-2, which also bound fibronectin in vitro.\",\n      \"method\": \"Quantitative cell adhesion assays, recombinant fragment analysis, actin cytoskeleton imaging (phalloidin staining), in vitro fibronectin binding assay\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — domain mapping with recombinant fragments plus functional cellular readout; multiple assays in a single rigorous study\",\n      \"pmids\": [\"14691143\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"LTBP-2 specifically binds the amino-terminal region of fibrillin-1 but not fibrillin-2, in a Ca2+-dependent manner (Kd = 9.4 nM). The major fibrillin-1 binding site resides near the C-terminus of LTBP-2. LTBP-2 and LTBP-1 compete for the same or adjacent binding site on fibrillin-1, suggesting LTBP-2 can act as a negative modulator of latent TGF-β complex storage on microfibrils.\",\n      \"method\": \"Solid phase binding assays, overlay blotting, recombinant fragment competition assays, EDTA/Ca2+ modulation, Kd calculation, immunohistochemistry of developing human aorta\",\n      \"journal\": \"Matrix biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstituted binding with Kd determination, domain mapping, competition assay, Ca2+ dependence; multiple orthogonal methods\",\n      \"pmids\": [\"17293099\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"LTBP-2 binds fibulin-5 (DANCE) and regulates elastic fiber assembly. Downregulation of LTBP-2 in human skin fibroblasts induces fibrillin-1-independent fibrillar deposition of fibulin-5 and elastin. Recombinant LTBP-2 promotes deposition of fibulin-5 onto fibrillin-1 microfibrils, indicating LTBP-2 regulates targeting of fibulin-5 to appropriate microfibrils for elastic fiber assembly.\",\n      \"method\": \"Yeast two-hybrid (implied by 'identification'), protein binding assays, siRNA knockdown of LTBP-2 in human fibroblasts, elastogenesis assay with confocal microscopy, recombinant LTBP-2 add-back experiment\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — siRNA loss-of-function plus recombinant protein rescue, multiple orthogonal readouts; highly cited\",\n      \"pmids\": [\"17581631\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"LTBP-2 matrix association depends on fibrillin-1. In cultured human embryonic lung fibroblasts, LTBP-2 was not deposited into ECM until after fibronectin and fibrillin-1 networks formed. LTBP-2 failed to assemble into ECM of fibronectin-deficient mouse fibroblasts. Lentiviral shRNA silencing of fibrillin-1 profoundly disrupted LTBP-2 deposition, demonstrating fibrillin-1 is required for LTBP-2 ECM incorporation.\",\n      \"method\": \"Metabolic labeling, immunoprecipitation, temporal ECM assembly analysis, fibronectin-null fibroblasts, lentiviral shRNA knockdown of fibrillin-1, immunofluorescence co-localization\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockdown (shRNA) plus null cell model with clear mechanistic readout; multiple orthogonal approaches\",\n      \"pmids\": [\"19681046\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Null mutations in LTBP2 cause primary congenital glaucoma. LTBP2 protein was localized to the anterior segment of the eye, specifically at the ciliary body and ciliary processes, suggesting a structural role in maintaining ciliary muscle tone and normal anterior chamber development.\",\n      \"method\": \"Homozygosity mapping, Sanger sequencing of LTBP2 in PCG families, immunohistochemistry of anterior eye segment\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — genetic loss-of-function (null mutations) with tissue localization; mechanism inferred from anatomy rather than direct functional assay\",\n      \"pmids\": [\"19361779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"LTBP-2 has multiple heparin/heparan sulfate binding sites. Solid-phase assays identified high-affinity binding to heparin (Kd ~0.9 nM for full-length LTBP-2). Three major heparin-binding sequences reside in the N-terminal fragment, including the sequence LTEKIKKIKIV in the first large cysteine-free domain adjacent to the fibulin-5 binding site. LTBP-2 interacts with cell-surface syndecan-4 and basement membrane perlecan heparan sulfate chains.\",\n      \"method\": \"Solid-phase heparin-albumin conjugate binding assays, recombinant fragment analysis, synthetic peptide inhibition, Kd determination, EDTA/EGTA modulation, specificity controls with chondroitin sulfate\",\n      \"journal\": \"Matrix biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — rigorous binding assays with Kd determination, domain and peptide-level mapping, specificity controls, proteoglycan interactions confirmed\",\n      \"pmids\": [\"20382221\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"LTBP2 mutations cause Weill-Marchesani syndrome. The homozygous missense mutation p.Val1177Met in LTBP2 was shown to cause autosomal recessive WMS/WM-like syndrome. Electron and fluorescence microscopy of patient skin showed disruptions of the microfibrillar network in the ECM, directly linking LTBP2 dysfunction to microfibrillar network integrity.\",\n      \"method\": \"Homozygosity mapping, Sanger sequencing, light/fluorescent/electron microscopy of patient ECM\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — genetic evidence plus direct ultrastructural demonstration of ECM disruption in patient tissue\",\n      \"pmids\": [\"22539340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"LTBP-2 competes with tropoelastin for binding to fibulin-5 and heparin, acting as a negative modulator of elastinogenesis. LTBP-2 bound fibulin-5 with Kd = 26.5 nM (similar affinity to tropoelastin-fibulin-5, Kd = 24.7 nM) and inhibited the tropoelastin-fibulin-5 interaction in a dose-dependent manner. LTBP-2 also significantly inhibited tropoelastin binding to heparin. Addition of exogenous LTBP-2 to chondrocyte cultures blocked elastinogenesis concentration-dependently.\",\n      \"method\": \"Solid-phase competitive binding assays, Kd calculation, confocal co-localization in fibroblast matrix, ear cartilage chondrocyte elastogenesis assay\",\n      \"journal\": \"Matrix biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — quantitative competitive binding with Kd values, functional elastogenesis assay, co-localization; multiple orthogonal methods\",\n      \"pmids\": [\"24148803\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"LTBP-2 is essential for formation of ciliary zonule microfibrils. Ltbp2−/− mice developed lens luxation due to compromised ciliary zonule formation. siRNA knockdown of LTBP2 in human ciliary epithelial cells disrupted microfibril meshwork formation. Supplementation with recombinant LTBP-2 rescued microfibril meshwork formation in knockdown cells and restored unfragmented bundled ciliary zonules in Ltbp2−/− mouse eyes under organ culture. Human mutant LTBP-2 proteins, despite retaining fibrillin-1-binding domains, failed to be secreted due to conformational alteration.\",\n      \"method\": \"Ltbp2 knockout mouse generation, siRNA knockdown in ciliary epithelial cells, recombinant LTBP-2 rescue in vitro and organ culture, secretion assay of mutant proteins\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — knockout mouse, siRNA knockdown, and recombinant protein rescue with multiple readouts; strong mechanistic evidence\",\n      \"pmids\": [\"24908666\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LTBP-2 has a single high-affinity binding site for FGF-2 (Kd = 1.1 nM) located in a central region consisting of six tandem EGF-like motifs (EGFs 9-14). This region also contains a heparin/heparan sulfate-binding site. LTBP-2 completely blocked FGF-2-stimulated fibroblast proliferation at 5-fold molar excess, demonstrating it is a potent inhibitor of FGF-2 bioactivity.\",\n      \"method\": \"Solid-phase binding assays, recombinant fragment mapping, Kd determination, FGF-2-stimulated fibroblast proliferation assay, confocal co-localization in keloid tissue\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — quantitative binding with Kd, domain mapping, functional proliferation inhibition assay; multiple orthogonal methods\",\n      \"pmids\": [\"26263555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LTBP-2 modulates NF-κB p65 signaling in nasopharyngeal carcinoma cells. Re-expression of LTBP-2 reduced phosphorylation of p65 at Serine 536, inhibited nuclear translocation of phosphorylated p65, and impaired p65 DNA-binding ability, resulting in downregulation of p65-related gene expression and tumor suppression.\",\n      \"method\": \"Loss- and gain-of-function (siRNA/overexpression), Western blotting for p-p65(Ser536), nuclear fractionation, DNA-binding assay (EMSA implied), colony formation, angiogenesis and EMT assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — multiple functional readouts with defined phosphorylation endpoint; single lab\",\n      \"pmids\": [\"25974126\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A 4-bp insertion in exon 8 of LTBP2 causing a frameshift causes primary congenital glaucoma in domestic cats, with histologically confirmed arrest of aqueous humor outflow pathway development. This establishes the feline model as the first spontaneous non-rodent model of PCG linked to LTBP2 mutation and confirms LTBP2's role in anterior segment development.\",\n      \"method\": \"Candidate gene linkage analysis (LOD 18.38), Sanger sequencing, ophthalmic phenotyping, histology of anterior segment\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — genetic loss-of-function with histological mechanistic readout in an orthologous animal model\",\n      \"pmids\": [\"27149523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"A central bioactive region of LTBP-2 (an 8-Cys motif flanked by four EGF-like repeats) stimulates TGF-β1 expression and secretion in fibroblasts via phosphorylation of both Akt and p38 MAPK signaling pathways. The TGF-β1 increase was due to transcriptional upregulation (not displacement of matrix-stored TGF-β1). Anti-αVβ3 integrin antibodies partially inhibited this effect, suggesting a direct or indirect role for αVβ3 integrin as receptor.\",\n      \"method\": \"Exogenous recombinant LTBP-2 and fragment addition to fibroblasts, ELISA for TGF-β1, kinase inhibitor experiments, phosphorylation Western blots (Akt, p38), function-blocking integrin antibodies\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — domain mapping plus signaling pathway dissection with specific inhibitors; single lab\",\n      \"pmids\": [\"28991210\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"LTBP2 knockdown in trabecular meshwork cells affected TGFβ and BMP signaling pathways, ECM gene expression, and apoptosis. Effects of LTBP2 knockdown paralleled those of oxidative stress induction, suggesting LTBP2 mediates its effects on trabecular meshwork ECM and apoptosis through TGFβ and BMP signaling pathway activation.\",\n      \"method\": \"siRNA knockdown, TGFβ2 and gremlin treatment, canonical TGFβ and BMP signaling assays, ECM gene expression analysis, apoptosis assays in primary human trabecular meshwork cells\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — siRNA knockdown with multiple pathway readouts; single lab, mechanism partially defined\",\n      \"pmids\": [\"29908281\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"LTBP2 knockdown in a rat dilated cardiomyopathy model reversed myocardial oxidative stress injury, fibrosis, and remodeling. The protective effects were mediated by downregulation of the NF-κB signaling pathway (reduced p65 and p52 levels). Activation of NF-κB pathway reversed the benefits of LTBP2 silencing, placing LTBP2 upstream of NF-κB in this context.\",\n      \"method\": \"siRNA knockdown in vivo (DCM rat model) and in vitro, NF-κB pathway activator co-treatment, hemodynamic measurements, collagen/ROS/cytokine quantification, Western blotting\",\n      \"journal\": \"Acta physiologica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo and in vitro knockdown with epistasis rescue experiment placing LTBP2 upstream of NF-κB\",\n      \"pmids\": [\"31512380\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LTBP-2 is required for mechanical strength and longevity of ciliary zonular fibers but not for their initial formation. In Ltbp2−/− mice, zonular fibers appeared structurally normal at birth but began to rupture by 2 months, with fully penetrant ectopia lentis by 6 months. LTBP-2 absence reduced ultimate tensile strength by ~50% and significantly altered viscoelastic behavior. Modeling indicated mutant fibers are prone to failure during saccadic eye movement.\",\n      \"method\": \"Ltbp2 knockout mouse, 3D zonule imaging, in vivo OCT imaging, mechanical tensile testing, quasi-linear viscoelastic modeling, harmonic oscillator simulation\",\n      \"journal\": \"Matrix biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — knockout mouse with quantitative mechanical testing and mathematical modeling; multiple orthogonal methods\",\n      \"pmids\": [\"33039488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LTBP2 mutation in an LTBP2/TCTN3 double-heterozygous patient delayed cardiomyocyte development. Using CRISPR/Cas9-generated human pluripotent stem cells carrying the LTBP2 mutation (p.Asp736Asn), differentiation into cardiomyocytes showed delayed CM development compared to wild type, with enrichment of pathways related to cardiac development and congenital heart disease.\",\n      \"method\": \"CRISPR/Cas9 gene editing of hPSCs, hPSC differentiation into cardiomyocytes, transcriptomics at differentiation days 0/9/13, pathway enrichment analysis\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single mutation in a compound variant background (LTBP2+TCTN3), transcriptomics-based pathway inference; difficult to isolate LTBP2-specific effect\",\n      \"pmids\": [\"33098376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Ltbp2−/− mice exhibit multiple organ phenotypes including altered body weight and fat mass, and effects on bone and skin development, with reduced tissue strength. Notably, tissues expressing high Ltbp2 levels, such as aorta and lung, showed no developmental or homeostatic phenotype, indicating tissue-specific roles for LTBP2 in ECM and signaling.\",\n      \"method\": \"Ltbp2 knockout mouse analysis, body composition measurement, bone and skin mechanical testing, histology\",\n      \"journal\": \"Developmental dynamics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — knockout mouse with multiple tissue phenotypes; mechanistic interpretation partially inferred\",\n      \"pmids\": [\"37688792\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HIF-1α directly binds to the LTBP2 promoter to transcriptionally activate LTBP2 expression. LTBP2 in turn interacts with LOXL1 (demonstrated by molecular docking and co-immunoprecipitation), and this interaction activates ERK signaling to promote hepatic stellate cell activation and EMT in liver fibrosis. AAV6-mediated knockdown of LTBP2 in HSCs markedly reduced CCl4-induced liver fibrosis.\",\n      \"method\": \"ChIP assay, dual-luciferase reporter assay, molecular docking, co-immunoprecipitation, AAV6-mediated in vivo knockdown, gain/loss-of-function in LX-2 cells, ERK pathway Western blotting\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP for promoter binding, Co-IP for protein interaction, in vivo knockdown with phenotypic readout; single lab\",\n      \"pmids\": [\"40244455\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HIF-1α transcriptionally activates LTBP2 by binding its promoter. LTBP2 promotes oral mucosal fibrosis (OSF) by activating NF-κB signaling. Curcumin inhibits HIF-1α, thereby reducing LTBP2 expression and inactivating NF-κB to alleviate arecoline-induced OSF. This defines HIF-1α → LTBP2 → NF-κB as a fibrosis-promoting axis.\",\n      \"method\": \"Dual-luciferase reporter assay for HIF-1α/LTBP2 promoter interaction, siRNA knockdown, qRT-PCR, Western blotting, MTT/transwell/flow cytometry assays, ELISA\",\n      \"journal\": \"Oral diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — luciferase assay demonstrates direct promoter binding; functional knockdown places LTBP2 in HIF-1α/NF-κB axis; single lab\",\n      \"pmids\": [\"37382472\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CAF-secreted LTBP2 interacts with integrin α6β4 on esophageal squamous cell carcinoma cells, activating Src signaling to promote metastasis and chemoresistance. Antagonistic antibodies targeting LTBP2 increased chemotherapy susceptibility. This identifies integrin α6β4 as a functional receptor for extracellular LTBP2.\",\n      \"method\": \"Co-immunoprecipitation (LTBP2/integrin α6β4), Src phosphorylation Western blotting, antagonistic antibody treatment, invasion/metastasis assays, chemoresistance assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP demonstrates binding, signaling assay confirms downstream activation, antibody intervention links to functional outcome; single lab\",\n      \"pmids\": [\"40245188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"LTBP2 deficiency reduces lung fibrosis in mice. Ltbp2−/− mice exposed to bleomycin or silica showed significantly reduced fibrosis versus wild-type, with reduced TGFβ signaling and impaired fibroblast migration in vitro. Transcriptomic analysis identified LTBP2-regulated genes including the antifibrotic lncRNA Airn. LTBP2 competes with the large latent TGFβ complex (LLC) for fibrillin N-terminus binding, and its loss promotes LLC sequestration and reduces active TGFβ release. However, Ltbp2−/− mice also showed impaired airway epithelial repair.\",\n      \"method\": \"Ltbp2 knockout mouse, bleomycin and silica fibrosis models, TGFβ signaling assays (pSmad), fibroblast wound closure assay, transcriptomics, naphthalene epithelial injury model\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — knockout mouse with two independent fibrosis models, signaling assays, and in vitro functional test; preprint, not yet peer-reviewed\",\n      \"pmids\": [\"40654695\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"LTBP2 knockout mice develop myxomatous mitral valve changes (histology and echocardiography). A human MVP-segregating LTBP2 mutation (V1506M knockin) reproduced the myxomatous valve phenotype. KO mice showed overexpression of TGFβ signaling targets RUNX2 and periostin in valve tissue, linking LTBP2 loss to dysregulated TGFβ signaling in valvular disease.\",\n      \"method\": \"LTBP2 knockout and knockin mouse generation, echocardiography, histology, qPCR for TGFβ target genes (periostin/POSTN, RUNX2, CTGF), exome sequencing with family segregation\",\n      \"journal\": \"European heart journal open\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — both KO and KI mouse models with multiple phenotyping methods and molecular pathway readout; single lab\",\n      \"pmids\": [\"39882270\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"LTBP2 is a large extracellular matrix glycoprotein of the fibrillin-LTBP superfamily that, uniquely among LTBPs, does not stably bind TGF-β; instead it binds fibrillin-1 (C-terminal site, Kd ~9 nM, Ca2+-dependent), fibulin-5, FGF-2 (central EGF-like region, Kd ~1 nM), heparan sulfate proteoglycans (syndecan-4, perlecan), and integrin α6β4, thereby acting as a structural microfibril component that regulates elastic fiber assembly by competing with tropoelastin for fibulin-5 and with the large latent TGF-β complex for fibrillin-1 binding, controls TGF-β bioavailability and signaling (including Akt/p38 and NF-κB pathways), mediates selective cell adhesion and antiadhesion through its N-terminal proline-rich region, and is essential for the mechanical strength of ciliary zonular fibers and normal development of the ocular anterior segment, cardiac valves, and multiple connective tissues.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"LTBP2 is a large extracellular matrix glycoprotein that integrates into fibrillin-1 microfibrils and modulates growth factor bioavailability, elastic fiber assembly, and ECM mechanical integrity across multiple tissues. LTBP2 binds the N-terminus of fibrillin-1 (Kd ~9 nM) in a Ca²⁺-dependent manner and competitively displaces LTBP-1 and the large latent TGF-β complex from this site, thereby promoting TGF-β release and signaling; Ltbp2-knockout mice accordingly show reduced TGF-β signaling and fibrosis, while valve tissue exhibits TGF-β target overexpression and myxomatous degeneration [PMID:17293099, PMID:39882270, PMID:40654695]. LTBP2 also sequesters FGF-2 via central EGF-like repeats (Kd ~1 nM) to inhibit fibroblast proliferation, competitively blocks tropoelastin–fibulin-5 interaction to negatively regulate elastogenesis, binds heparan sulfate proteoglycans (syndecan-4, perlecan), and exerts antiadhesive effects on fibroblasts through its N-terminal proline-rich domain [PMID:26263555, PMID:24148803, PMID:20382221, PMID:14691143]. Loss-of-function mutations in LTBP2 cause primary congenital glaucoma, Weill-Marchesani syndrome, and myxomatous mitral valve disease in humans, with knockout mice confirming that LTBP2 confers mechanical strength to zonular fibers and trabecular meshwork elastic fibers without being required for their initial formation [PMID:19361779, PMID:22539340, PMID:33039488, PMID:39432401].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Identification of LTBP-2 as a new ECM glycoprotein related to LTBP-1 and fibrillins established the gene family and showed that LTBP-2 can complex with TGF-β1 precursor, raising the question of whether it directly regulates TGF-β storage.\",\n      \"evidence\": \"cDNA cloning, co-transfection of LTBP-2 and TGF-β1 in human fibroblasts, metabolic labeling/SDS-PAGE\",\n      \"pmids\": [\"7798248\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LTBP-2 covalently binds latent TGF-β in vivo was not resolved\", \"No ECM localization partner identified\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Demonstration that LTBP-2 TGF-bp repeats can covalently bind the small latent TGF-β1 complex via disulfide bonds refined the biochemical basis for LTBP-2–TGF-β interaction.\",\n      \"evidence\": \"Immunoprecipitation and SDS-PAGE with mouse LTBP-2 TGF-bp repeats\",\n      \"pmids\": [\"9602168\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single study; independent replication lacking\", \"Physiological relevance of covalent binding not established in vivo\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Mapping of antiadhesive activity to the N-terminal proline-rich domain revealed that LTBP-2 is not merely a structural scaffold but actively modulates cell–matrix interactions, disrupting fibroblast adhesion and actin organization.\",\n      \"evidence\": \"Quantitative cell adhesion assays, recombinant domain fragments, actin staining on fibronectin substrates\",\n      \"pmids\": [\"14691143\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor mediating antiadhesive effect not identified\", \"In vivo significance of antiadhesive function unknown\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Determining that LTBP-2 binds fibrillin-1's N-terminus with nanomolar affinity and competes with LTBP-1 for this site provided a mechanism by which LTBP-2 could displace the large latent TGF-β complex from microfibrils, modulating TGF-β bioavailability.\",\n      \"evidence\": \"Solid-phase binding assay with Kd determination, competitive displacement, domain mapping, Ca²⁺ dependence\",\n      \"pmids\": [\"17293099\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo displacement of LLC by LTBP-2 not demonstrated\", \"Whether competition occurs in specific tissues was unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Two parallel advances established LTBP-2's fibrillin-1-dependent ECM assembly and its essential role in the eye: knockdown showed that a pre-existing fibrillin-1 network is required for LTBP-2 matrix incorporation, while human genetic studies linked loss-of-function LTBP2 mutations to primary congenital glaucoma.\",\n      \"evidence\": \"shRNA knockdown and fibronectin-null fibroblasts for assembly; homozygosity mapping and Sanger sequencing in consanguineous families with immunohistochemistry of anterior segment\",\n      \"pmids\": [\"19681046\", \"19361779\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which LTBP2 loss causes glaucoma not resolved at the molecular level\", \"Whether fibrillin-1 dependence is absolute in all tissues unclear\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identification of multiple heparin/heparan sulfate binding sites and specific interactions with syndecan-4 and perlecan expanded the interactome of LTBP-2 to include cell-surface and basement-membrane proteoglycans.\",\n      \"evidence\": \"Solid-phase binding with Kd measurements, peptide competition, recombinant fragment mapping\",\n      \"pmids\": [\"20382221\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of syndecan-4 or perlecan binding for signaling not tested\", \"In vivo relevance not demonstrated\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"A homozygous LTBP2 missense mutation causing Weill-Marchesani syndrome with disrupted microfibrillar ultrastructure in patient skin directly linked LTBP2 to microfibril integrity in a connective tissue disorder beyond glaucoma.\",\n      \"evidence\": \"Homozygosity mapping, Sanger sequencing, electron microscopy of patient skin ECM\",\n      \"pmids\": [\"22539340\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single family reported\", \"How a missense change disrupts microfibrils mechanistically not resolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrating that LTBP-2 binds fibulin-5 and competitively blocks tropoelastin–fibulin-5 interaction to inhibit elastogenesis revealed a direct negative regulatory role in elastic fiber assembly.\",\n      \"evidence\": \"Solid-phase binding (Kd ~26 nM), competitive binding assay, chondrocyte elastinogenesis assay\",\n      \"pmids\": [\"24148803\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo validation of elastogenesis inhibition in LTBP2 KO not performed\", \"Tissue specificity of this inhibitory role unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identification of a single high-affinity FGF-2 binding site (Kd ~1 nM) in central EGF-like repeats, with functional demonstration that LTBP-2 abolishes FGF-2-driven proliferation, established LTBP-2 as a potent extracellular growth factor sequestrant beyond TGF-β.\",\n      \"evidence\": \"Solid-phase binding with recombinant fragments, Kd determination, fibroblast proliferation assay\",\n      \"pmids\": [\"26263555\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of FGF-2 sequestration not tested in KO models\", \"Whether other FGFs are also bound is unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Re-expression experiments in NPC cells showed LTBP-2 suppresses NF-κB p65 phosphorylation, nuclear translocation, and DNA binding, revealing a signaling function beyond ECM scaffolding.\",\n      \"evidence\": \"Overexpression/knockdown, Western blot phosphorylation analysis, nuclear fractionation, EMSA\",\n      \"pmids\": [\"25974126\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking extracellular LTBP-2 to intracellular NF-κB not identified\", \"Cell-type specificity not addressed\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"A spontaneous frameshift mutation in feline LTBP2 causing PCG with arrested postnatal anterior chamber development provided the first non-rodent genetic model, confirming the structural requirement for LTBP2 in aqueous outflow pathway morphogenesis.\",\n      \"evidence\": \"Linkage analysis (LOD 18.38), Sanger sequencing, histological examination of feline anterior segment\",\n      \"pmids\": [\"27149523\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism downstream of LTBP2 loss in TM cells not dissected\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"A central bioactive region of LTBP-2 was shown to upregulate TGF-β1 expression in fibroblasts via Akt/p38 MAPK, partially involving αVβ3 integrin, linking an LTBP-2 domain to an active signaling cascade rather than passive sequestration.\",\n      \"evidence\": \"Recombinant fragment stimulation of fibroblasts, kinase inhibitors, anti-integrin blocking antibodies, ELISA\",\n      \"pmids\": [\"28991210\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct receptor for this fragment not conclusively identified\", \"αVβ3 involvement was partial and not independently confirmed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"LTBP2 knockout mice revealed that LTBP-2 is dispensable for zonular fiber formation but essential for their mechanical strength, with ~50% reduction in tensile strength leading to progressive ectopia lentis — separating structural assembly from biomechanical function.\",\n      \"evidence\": \"Ltbp2-KO mouse, 3D imaging, OCT, stress-strain mechanical testing, viscoelastic modeling\",\n      \"pmids\": [\"33039488\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis for reduced mechanical strength (cross-linking, protein composition) not defined\", \"Rescue experiments not performed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Multi-organ phenotyping of LTBP2 KO mice revealed tissue-specific roles in bone, skin, and body composition but no overt phenotype in aorta or lung, demonstrating context-dependent function despite broad expression.\",\n      \"evidence\": \"Ltbp2-KO mouse, biomechanical testing, histology, body composition analysis\",\n      \"pmids\": [\"37688792\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Why aorta and lung are spared despite high expression is unexplained\", \"Compensatory mechanisms not investigated\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Ultrastructural time-course analysis of feline LTBP2-mutant trabecular meshwork showed that elastic fiber disorganization precedes cellular and architectural changes, establishing ECM structural failure as the initiating event in LTBP2-associated glaucoma.\",\n      \"evidence\": \"Transmission electron microscopy at postnatal time points in LTBP2-mutant vs. control cats\",\n      \"pmids\": [\"39432401\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular composition of the defective elastic fibers not characterized\", \"Whether TGF-β dysregulation contributes to TM pathology not tested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Three studies expanded LTBP2 function: KO and knockin mice showed LTBP2 prevents myxomatous valve degeneration through TGF-β modulation; CAF-secreted LTBP2 was found to bind integrin α6β4 and activate Src in ESCC; and LTBP2 was shown to interact with LOXL1 via ERK signaling to promote hepatic stellate cell activation downstream of HIF-1α.\",\n      \"evidence\": \"KO/knockin mice with echocardiography and histology; Co-IP and integrin blocking in ESCC; ChIP, Co-IP, and AAV6-KD in CCl4 liver fibrosis model\",\n      \"pmids\": [\"39882270\", \"40245188\", \"40244455\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Integrin α6β4 as a direct receptor requires independent validation\", \"LOXL1 interaction identified by docking and single Co-IP\", \"How LTBP2 loss causes opposite TGF-β outcomes (increased in valve, decreased in lung fibrosis) is not reconciled\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the identity of cell-surface receptors through which LTBP-2 signals in different tissues; how LTBP-2 produces opposing TGF-β signaling outcomes (suppression in valve, promotion in lung fibrosis); the structural basis for LTBP-2's contribution to microfibril mechanical properties; and whether LTBP-2 has additional growth factor ligands beyond FGF-2 and TGF-β.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No atomic-resolution structure of LTBP-2 or its complexes\", \"No unbiased interactome screen reported\", \"In vivo roles of FGF-2 sequestration untested in KO models\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [3, 8, 9, 10]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [4, 7, 12, 20]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [0, 2, 4, 7, 8, 11, 12]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 3, 9]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [10, 13, 17, 22]},\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [4, 7, 8, 12, 20]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [5, 14, 23]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"FBN1\",\n      \"FBLN5\",\n      \"FGF2\",\n      \"SDC4\",\n      \"HSPG2\",\n      \"LOXL1\",\n      \"ITGB4\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"LTBP2 is a large extracellular matrix glycoprotein of the fibrillin-LTBP superfamily that serves as a structural component of microfibrils and a multifunctional regulator of growth factor bioavailability, elastic fiber assembly, and connective tissue integrity. Unlike other LTBPs, LTBP2 does not stably bind TGF-β isoforms; instead it binds fibrillin-1 (Kd ~9 nM, Ca²⁺-dependent) and competes with the large latent TGF-β complex for fibrillin-1 binding, thereby modulating TGF-β storage and release, and also binds fibulin-5 (Kd ~27 nM), competing with tropoelastin to negatively regulate elastinogenesis [PMID:10930463, PMID:17293099, PMID:24148803, PMID:40654695]. LTBP2 additionally binds FGF-2 with high affinity (Kd ~1 nM) to inhibit FGF-2-driven proliferation, interacts with heparan sulfate proteoglycans (syndecan-4, perlecan) and integrin α6β4, and signals through Akt/p38, NF-κB, and Src pathways in cell-type-dependent contexts [PMID:26263555, PMID:20382221, PMID:40245188, PMID:28991210]. Loss-of-function mutations in LTBP2 cause primary congenital glaucoma and Weill-Marchesani syndrome in humans, and Ltbp2-null mice develop ectopia lentis from mechanically weakened ciliary zonular fibers, myxomatous mitral valve disease with dysregulated TGF-β signaling, and reduced fibrotic responses in the lung [PMID:19361779, PMID:22539340, PMID:33039488, PMID:39882270].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Identification of LTBP-2 as a novel ECM glycoprotein structurally related to LTBP-1 that associates with TGF-β1 precursor and the extracellular matrix established the founding member context for subsequent functional studies.\",\n      \"evidence\": \"cDNA cloning, recombinant co-transfection with TGF-β1, immunoprecipitation, and ECM association assay in COS cells\",\n      \"pmids\": [\"7798248\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological significance of the TGF-β1 association was unclear\", \"In vivo ECM localization not determined\", \"Binding stoichiometry and affinity not measured\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Resolving a contradiction with the 1994/1998 findings, domain-swap mutagenesis demonstrated that LTBP-2 uniquely among LTBPs lacks TGF-β binding capacity due to absence of a critical motif in its third 8-Cys repeat, fundamentally redefining its functional identity.\",\n      \"evidence\": \"In vitro binding assays with purified 8-Cys repeat fragments and domain-swap mutagenesis introducing the LTBP-1 TGF-β-binding motif into LTBP-2\",\n      \"pmids\": [\"10930463\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"If not TGF-β binding, the primary biological function of LTBP-2 remained unknown\", \"In vivo consequences of this distinction were untested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Mapping of dual adhesive and antiadhesive activities to the N-terminal proline-rich region of LTBP-2 revealed it as a cell-type-selective modulator of cell-matrix interactions operating through β1 integrins and heparan sulfate.\",\n      \"evidence\": \"Recombinant fragment adhesion assays, integrin-blocking antibodies, heparin inhibition on melanoma cells; antiadhesion and fibronectin-binding assays on fibroblasts\",\n      \"pmids\": [\"12716902\", \"14691143\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific integrin heterodimer(s) mediating the antiadhesive effect on fibroblasts were not defined\", \"In vivo relevance of the adhesion/antiadhesion duality was not tested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Two landmark findings — high-affinity Ca²⁺-dependent binding of LTBP-2 to fibrillin-1 (Kd ~9 nM) with competition against LTBP-1, and binding to fibulin-5 to regulate elastic fiber assembly — established LTBP-2 as a structural microfibril component that indirectly controls TGF-β storage and elastogenesis.\",\n      \"evidence\": \"Solid-phase binding with Kd determination and competition assays for fibrillin-1; siRNA knockdown and recombinant rescue for fibulin-5/elastin deposition in human fibroblasts\",\n      \"pmids\": [\"17293099\", \"17581631\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LTBP-2 displaces the large latent TGF-β complex from fibrillin-1 in vivo was not directly shown\", \"Stoichiometry of LTBP-2 within microfibril bundles was unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Discovery that LTBP2 null mutations cause primary congenital glaucoma in humans, with LTBP-2 localized to the ciliary body, linked this structural ECM protein to a specific Mendelian ocular disease and anterior segment development.\",\n      \"evidence\": \"Homozygosity mapping and Sanger sequencing in PCG families; immunohistochemistry of human anterior eye segment\",\n      \"pmids\": [\"19361779\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism by which LTBP-2 loss disrupts aqueous outflow was not determined\", \"Whether glaucoma results from structural or signaling defects was unclear\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identification of multiple high-affinity heparin-binding sites and interactions with syndecan-4 and perlecan expanded the LTBP-2 interactome to heparan sulfate proteoglycans, providing a molecular basis for its cell-surface and basement membrane interactions.\",\n      \"evidence\": \"Solid-phase binding with recombinant fragments, synthetic peptide inhibition, Kd determination (~0.9 nM)\",\n      \"pmids\": [\"20382221\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of syndecan-4/perlecan binding on signaling or ECM assembly was not tested\", \"Whether HSPG interactions are required for LTBP-2 ECM incorporation was not addressed\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Quantitative competition assays showing LTBP-2 displaces tropoelastin from fibulin-5 (comparable Kd values ~25 nM) and blocks elastinogenesis in chondrocytes established LTBP-2 as a negative modulator of elastic fiber assembly.\",\n      \"evidence\": \"Competitive solid-phase binding assays with Kd determination; exogenous LTBP-2 addition to chondrocyte elastogenesis cultures\",\n      \"pmids\": [\"24148803\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo elastic fiber phenotype of LTBP-2 deficiency in elastic tissues (aorta, lung) was not characterized at this point\", \"Temporal regulation of competition was unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Ltbp2 knockout mice developed progressive lens luxation from ciliary zonule fiber failure, and recombinant LTBP-2 rescued microfibril formation in both knockdown cells and KO organ cultures, proving LTBP-2 is essential for zonular fiber integrity.\",\n      \"evidence\": \"Ltbp2−/− mice, siRNA in ciliary epithelial cells, recombinant protein rescue in vitro and organ culture, mutant protein secretion assay\",\n      \"pmids\": [\"24908666\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LTBP-2 is a load-bearing structural element or an assembly catalyst was unresolved\", \"The mechanism by which human LTBP2 mutations cause glaucoma versus ectopia lentis was unexplained\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Discovery that LTBP-2 binds FGF-2 with very high affinity (Kd ~1 nM) through central EGF-like repeats and completely blocks FGF-2-stimulated proliferation expanded LTBP-2's role from a structural/TGF-β modulator to a broader growth factor sequestrant.\",\n      \"evidence\": \"Solid-phase binding with recombinant fragments, Kd determination, FGF-2-stimulated fibroblast proliferation inhibition assay\",\n      \"pmids\": [\"26263555\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo significance of FGF-2 sequestration was not tested\", \"Whether FGF-2 binding affects LTBP-2 matrix assembly or fibrillin interactions was unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"A central bioactive fragment of LTBP-2 was shown to stimulate TGF-β1 transcription via Akt and p38 MAPK signaling, partially through αVβ3 integrin, revealing that LTBP-2 does not merely sequester growth factors but also actively triggers signaling cascades.\",\n      \"evidence\": \"Recombinant fragment addition to fibroblasts, ELISA, kinase inhibitors, phosphorylation Western blots, integrin-blocking antibodies\",\n      \"pmids\": [\"28991210\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The direct receptor for the LTBP-2 fragment was not definitively identified\", \"Whether this signaling occurs during normal ECM remodeling or only pathologically was unclear\", \"Single lab finding not independently replicated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Mechanical testing of Ltbp2−/− ciliary zonules quantitatively demonstrated ~50% reduction in ultimate tensile strength and altered viscoelasticity, establishing LTBP-2 as a structural reinforcer required for long-term mechanical resilience rather than initial fiber formation.\",\n      \"evidence\": \"Ltbp2 knockout mouse, tensile testing, 3D imaging, quasi-linear viscoelastic modeling, harmonic oscillator simulation of saccadic eye movement\",\n      \"pmids\": [\"33039488\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The molecular mechanism of mechanical reinforcement (cross-linking, bundling, stiffening) was not defined\", \"Whether this mechanical role extends to other microfibril-rich tissues was unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Multiple studies converged on a HIF-1α → LTBP2 → NF-κB/ERK fibrosis-promoting axis, showing HIF-1α directly binds the LTBP2 promoter and that LTBP2 activates NF-κB signaling in fibrotic contexts and interacts with LOXL1 to activate ERK in hepatic stellate cells.\",\n      \"evidence\": \"ChIP and dual-luciferase reporter assays for HIF-1α/promoter binding; co-immunoprecipitation of LTBP2-LOXL1; AAV6-mediated in vivo knockdown reducing liver fibrosis; siRNA studies in oral fibrosis models\",\n      \"pmids\": [\"40244455\", \"37382472\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether LTBP2-LOXL1 interaction is direct or bridged by ECM components needs confirmation beyond co-IP and docking\", \"How extracellular LTBP2 activates intracellular NF-κB — the receptor/transducer is undefined\", \"Replication in independent labs needed\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identification of integrin α6β4 as a functional cell-surface receptor for LTBP2, activating Src signaling to drive metastasis and chemoresistance in esophageal cancer, provided the first defined receptor-signaling axis for extracellular LTBP2.\",\n      \"evidence\": \"Co-immunoprecipitation of LTBP2 with integrin α6β4, Src phosphorylation assays, antagonistic antibody treatment in cancer cells\",\n      \"pmids\": [\"40245188\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Binding site on LTBP2 for integrin α6β4 not mapped\", \"Whether this receptor mediates LTBP2 signaling in non-cancer contexts is unknown\", \"Single study without reciprocal knockout validation\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Ltbp2 knockout mice showed myxomatous mitral valve disease with TGF-β target upregulation (RUNX2, periostin), and a human knockin of a MVP-segregating LTBP2 variant recapitulated this phenotype, establishing LTBP2 as a regulator of cardiac valve homeostasis via TGF-β pathway modulation.\",\n      \"evidence\": \"KO and knockin mouse models, echocardiography, histology, qPCR for TGF-β targets, exome sequencing with family segregation\",\n      \"pmids\": [\"39882270\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether valve disease results from increased active TGF-β release or altered ECM mechanics is not resolved\", \"Long-term progression and penetrance in heterozygotes not characterized\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Major unresolved questions include the structural basis of LTBP-2's mechanical reinforcement of microfibrils, the identity and hierarchy of cell-surface receptors mediating LTBP-2's intracellular signaling in non-cancer tissues, and why LTBP2 loss produces organ-specific phenotypes despite broad expression.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No atomic-resolution structure of LTBP-2 or its complexes exists\", \"The receptor hierarchy (integrin α6β4, αVβ3, HSPGs) for LTBP2 signaling is not unified\", \"Tissue-specific phenotypic selectivity in KO mice is mechanistically unexplained\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [2, 8, 13, 20]},\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [4, 5, 25]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [6, 7, 12, 14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [0, 2, 6, 7, 8, 10, 11, 13]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 14, 25]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [2, 6, 7, 8, 11, 12, 13, 20]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [15, 17, 19, 24, 25]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [9, 13, 16, 27]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"FBN1\",\n      \"FBLN5\",\n      \"FGF2\",\n      \"SDC4\",\n      \"HSPG2\",\n      \"ITGB4\",\n      \"LOXL1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}